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Abstract 
 
Type 2 diabetes has increased in prevalence globally in recent years, mainly due to 
obesity.  Many other risk factors are well known.  Identifying those at high risk of type 
2 diabetes may guide targeted interventions aimed at reducing risk.   
 
Type 2 diabetes risk prediction is a complex science.  The first half of this thesis 
presents a quantitative and qualitative systematic review of 145 risk prediction models 
and scores.  Many are available; few are usable in real life clinical practice.  Seven have 
high potential to be used with routine data (such as electronic primary care records).   
 
The second half of this thesis describes the use of one of the risk prediction scores 
locally, the QDScore, on a dataset of 519,288 electronic primary care records in East 
London, UK to calculate the ten year risk of developing type 2 diabetes.  Ten percent of 
the population were at high risk (defined as a ten year risk of greater than 20%).  
Ethnicity and deprivation were key factors responsible for increasing risk, and there was 
overlap with cardiovascular morbidity.  A sub-section of these data were mapped to 
explore the feasibility of using geospatial mapping to convey the risk of non-
communicable disease in a public health setting.   
 
Previous research has focussed on targeting individuals with pre-diabetes (e.g. Impaired 
Fasting Glucose) and screening for undiagnosed diabetes.  Going a step further back 
and identifying those at risk of type 2 diabetes is theoretically possible due to the wide 
availability of prediction algorithms, and such an approach is potentially achievable 
locally using electronic primary care records.  This produces important descriptive data 
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to aid the interventions of general practitioners, public health specialists and urban 
planners.  Future research should focus on interventions which reduce risk of type 2 
diabetes in otherwise healthy adults.   
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SECTION 1: Overview 
Chapter 1: How this research came about 
 
In December 2010, the opportunity arose as part of my registrar training in public 
health, to undertake a full-time academic attachment in the Centre for Primary Care and 
Public Health at Queen Mary, University of London.  Previously I had worked in 
general surgery, as a clinical adviser to the Chief Medical Officer, and as a public health 
registrar at the Health Protection Agency and Tower Hamlets Primary Care Trust 
(PCT).  My family and I also live in Tower Hamlets.  For this reason, I was familiar 
with the demography of the area, particularly the ethnic diversity and deprivation, and 
health needs of this part of London.   
 
My professional work-related skills have always been general in nature.  My most 
enjoyable period of time clinically was working in an acting middle-grade position in 
general surgery in a District General Hospital in Oxfordshire.  At the Department of 
Health I worked on multiple different health policy agendas ranging from paediatrics to 
patient safety to pandemic flu.  At PCT level I enjoyed working across a wide range of 
commissioning agendas and at the Health Protection Agency I work as first on-call for 
communicable disease control for a population of 2.7 million.   
 
I met with Professor Trisha Greenhalgh and Dr. John Robson to discuss my academic 
placement towards the end of 2010.  It was clear that there was an interest from all 
parties in quantifying the risk of developing type 2 diabetes for the local population in 
Inner North East London (INEL - which includes Tower Hamlets, Newham and City & 
Hackney – in this thesis referred to as East London).  This was also of interest to the 
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three PCTs in the same geographical area, and this enabled an arrangement whereby my 
academic attachment would produce a report for the PCTs on type 2 diabetes risk.  It 
was proposed that I undertake a cross-sectional study using an algorithm called the 
QDScore which had been previously validated to predict ten year risk of developing 
type 2 diabetes using electronic primary care records.  I approached this project 
enthusiastically as it met the service aim of producing a high quality report for the PCTs 
that would be useful for commissioning, and also had the potential to meet an academic 
aim and contribute to the knowledge base and generate a high-quality publication.  It 
also became apparent early on that this could form the basis of a Doctoral thesis.   
 
My first task was to explore the literature of diabetes risk scoring, which I initially 
found complex.  The science of prognostic models and diabetes risk scores was 
statistically complex, and did not seem to me to be standardised and it was not 
accessible to a general medical reader.  I initially wondered whether it would be 
possible for me, as a public health doctor interested in the practical application of risk 
scores in an area of high deprivation and high diabetes prevalence, to continue with the 
project.  As I compiled a set of 29 papers on diabetes risk scores, two things became 
clear: [a] the heterogeneity between the studies were very high, to the extent that they 
were barely comparable, and [b] I was surprised that given a ‘quick’ literature search 
had produced so many papers, no systematic review existed.  Therefore this gave me the 
idea that perhaps the best way for me to understand this complex literature was to 
propose doing a systematic review of diabetes risk scores.   
 
Circumstances favoured this choice.  The academic centre to which I was attached had 
an emerging interest in systematic review.  Professor Khalid Khan’s team had recently 
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moved from Birmingham and were undertaking Cochrane reviews in women’s health, 
and Dr Catherine Meads from this team was able to offer some input to the diabetes 
work.  Professor Trisha Greenhalgh’s team were leading an international collaboration 
to develop guidance for realist reviews.  Some delays had arisen in obtaining the 
QDScore algorithm and so time was available to work on the review with the funded 
analyst for the cross-sectional study, Ms. Rohini Mathur.  Professor Trisha Greenhalgh 
was keen to support me conducting the review, and after looking at a few of the papers 
she suggested that this dataset would be amenable to qualitative (realist) analysis 
focusing on how (if at all) risk scores were used in real life clinical practice, and what 
the authors intended to be done with the risk scores they were creating.   
 
We added Dr. Tom Dent to the team, who as a public health consultant had considerable 
expertise in the applied science of using risk models and scores.  From January to June 
2011, I project managed and led this team to produce a mixed-method systematic 
review of diabetes risk models and scores.  We reviewed 145 different models and 
scores and performed an extensive quantitative and qualitative analysis.  These were 
summarised in an academic paper which was published in the British Medical Journal in 
November 2011.   
 
Although I was correct in assuming that no published systematic review existed when I 
embarked on this piece of secondary research, the journey took an interesting turn soon 
afterwards.  I learnt that a team from the University of Oxford (where I read medicine) 
and another team from the University of Cambridge were also conducting systematic 
reviews on similar but not identical research questions, which they also planned to 
publish in mid-late 2011.  A race against the ‘dark blues’ and the ‘light blues’ gave this 
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work an interesting competitive edge, though the different disciplinary origins of the 
three principal investigators, public health, statistics and epidemiology, meant that the 
three reviews, ultimately published within a few months of each other, had a different 
focus and complemented rather than duplicated one other.  Between the three teams we 
have produced a useful resource on diabetes risk scores from different perspectives.  As 
the National Institute for Health and Clinical Excellence (NICE) were, and are, 
producing guidelines on risk of type 2 diabetes, all three teams collaborated after the 
publication of the papers so as to feed consistent advice into that process.   
 
Following submission of the systematic review for publication, the QDScore algorithm 
became available.  Working with Dr. John Robson and Ms. Rohini Mathur it was run on 
a cross-sectional dataset of 519,288 electronic primary care records, calculating ten-year 
risk of type 2 diabetes.  Multiple pages and tables of data were produced.  When I had 
previously worked at Tower Hamlets PCT, using geospatial mapping to represent 
Hospital Episode Statistics had been very successful as part of a Care Closer to Home 
initiative.  However, it had not been an academically robust exercise, but had whetted 
my appetite for the usefulness of geospatially displaying health related data in a public 
health setting.  Professor Trisha Greenhalgh and Dr. John Robson were supportive for 
me to display the type 2 diabetes risk data in geographical maps.  This led to me 
working closely with Dr. Dianna Smith from the Department of Geography at Queen 
Mary, who (coincidentally) had conducted her PhD on geographical mapping of 
diabetes prevalence.  Individual postcodes were only available for one of the three PCTs 
(about a third of the dataset), but with these data from 157,045 records, we mapped risk 
of type 2 diabetes in Tower Hamlets only.  We also decided to explore the use of a new 
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mapping method called ring mapping and explored the theoretical possibilities of using 
this for health needs assessment.   
 
In the course of designing the maps we discovered that there was no systematic or 
consistent information governance guidance for researchers who sought to use 
postcodes for geospatial mapping.  This led to much discussion amongst the research 
team and with the National Information Governance Board (NIGB) and we explored the 
issues in detail.  There were two principle issues: [a] extracting postcodes (which are 
considered identifiable data) had to be done in a secure way according to an agreed 
protocol, and [b] representing small numbers of people on any mapping segment had to 
be handled in a way which meant it would not be possible to identify an individual.   
 
This second half of the project based on the cross-sectional analysis has resulted in three 
further academic papers: one on the uses of geospatial maps, which was published by 
British Medical Journal Open in February 2012; one on the information governance 
implications of geospatial mapping of small area data which at the time of writing is 
under review for BioMed Central Public Health; and the results from the overall cross-
sectional analysis, which at the time of writing are under review for the British Journal 
of General Practice.  The report to the PCTs contains a condensed version of this 
Doctoral thesis covering most of the work described above, and some extra data at the 
level of an individual PCT not included in the thesis.   
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Thesis structure 
 
Chapter 2 concludes section 1 and gives an overview of the epidemiology of type 2 
diabetes.  Section 2 covers the systematic review of diabetes risk scores.  Chapter 3 
covers the background, aims and methods of the review, and Chapter 4 the results and 
discussion.    
 
Section 3 covers the cross-sectional analysis of 519,288 electronic primary care records.  
Chapter 5 covers the background, aims and methods of the analysis, and Chapter 6 the 
results and discussion.   
 
Section 4 covers the geospatial mapping of 157,045 electronic primary care records.  
Chapter 7 covers the background, aims and methods of the analysis, and Chapter 8 the 
results and discussion.  The discussion also includes a consideration of some of the 
information governance issues and an analysis of the media coverage.   
 
Finally, Section 5 brings together in Chapter 9 the summary of key findings from across 
Sections 1-3, considers implications for policy, practice and research, and concludes 
with a personal reflection on the research including lessons learned and key challenges.   
 
I have inserted key tables, boxes, figures and maps in the main body of the thesis to aid 
readability.  The appendices contain copies of the academic papers and relevant 
checklists and search strategies linked to the systematic review.  I have sought 
throughout to make this accessible to a general medical and public health audience.   
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Chapter 2: Type 2 Diabetes Epidemiology 
 
Diabetes is becoming alarmingly common throughout the world.
1
  In this chapter I give 
an overview of type 2 diabetes epidemiology.  Whilst working on the systematic review, 
the cross-sectional study, and the geospatial mapping (all described later), this context 
provided motivation to quantify and highlight the extent of risk of type 2 diabetes.  
Although researching risk of type 2 diabetes is different from the epidemiology of 
established disease, the two are intimately interconnected.  Long term efforts to reduce 
risk of type 2 diabetes has the potential to dramatically decrease incidence.  I have 
divided this chapter into three sections: Global, United Kingdom, and East London.  
Many different studies and methodologies exist for estimating current and future 
incidence and prevalence of diabetes.  I have sought to summarise headline figures, 
combined with a more in-depth review of a few selected predictions.   
 
Global 
 
Almost 350 million people have diabetes worldwide, and the number expected to die 
from this cause is predicted to double between 2005 and 2030.
2
  Type 2 diabetes 
accounts for approximately 90% of cases.  Diabetes is one of four non-communicable 
diseases – diabetes, cardiovascular disease, chronic respiratory disease and cancers – 
which account for 60% of global deaths.
3
  Their cumulative financial burden worldwide 
in 2008 was estimated to be US$2.35 trillion and prevalence of disease is projected to 
increase exponentially.
4
  By 2010, the prevalence of diabetes in the adult populations of 
UK, USA, mainland China and United Arab Emirates had exceeded 7%,
5
 11%,
6
 15%
7
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and 17%
8
 respectively.  Americans born in 2000 or later have a lifetime risk of more 
than one in three of developing diabetes.
9
 
 
Global prevalence of both type 1 and type 2 diabetes was estimated for 2000 and 2030, 
in the year 2000.
10
  Differentiating between type 1 and type 2 diabetes was not possible 
as this was not coded in most data.  Forty prevalence studies from multiple countries 
were selected from the literature based on standard criteria for diagnosis of diabetes 
(e.g. Oral Glucose Tolerance Test – OGTT).  Using these countries’ age and sex-
specific estimates, extrapolations were made to similar countries without data, based on 
factors such as ethnicity, socioeconomic status and expert opinion (e.g. Australia’s 
prevalence was applied to New Zealand).   In developing countries, increasing 
urbanisation was assumed to be linked with double or more the risk of diabetes (e.g. due 
to reduced physical activity and obesity).  This was as opposed to developed countries 
where evidence suggested that urban and rural prevalence of diabetes was comparable.  
Population estimations and projections from the United Nations Population Division 
were used.  Total number of cases was projected to increase by almost 200 million, 
from 171 million to 366 million between 2000 and 2030.  This represents an increase in 
global prevalence from 2.8% to 4.4%.  The Middle East, Africa and India will see the 
largest relative increases, and the largest total number of cases will be in India (which is 
predicted to increase from 31.7 to 79.4 million).  More women than men have diabetes, 
since women live longer and diabetes increases with age, although overall prevalence is 
higher in men.  These predictions are concerning enough, but are almost certainly an 
under-estimate since they assume that obesity rates will remain static in developed 
countries or will follow rates of urbanisation in low income countries.   
 
23 
 
United Kingdom 
 
In the UK (United Kingdom) there are estimated to be 400 new diagnoses of diabetes 
every day and 90% of cases are classified as type 2 diabetes.
11
  Currently in England 
approximately 3.1 million people age 16 and above have diabetes.  This figure is 
expected to increase to 4.6 million by 2030, as a result of ageing, changes in the ethnic 
composition of the population, and rising obesity prevalence.
5
    
 
An estimation of the prevalence and incidence covering all of the UK between 1996-
2005 was published in 2008.
12
  Data on people aged 10-79 years were extracted from 
the THIN (The Health Improvement Network) database, a collection of almost 5 million 
electronic general practitioner records.  After exclusion criteria were applied 1.84 
million records were analysed.  Incident cases were defined as those recorded as a new 
diagnosis between 1996-2005 (numerator - number of new cases/denominator - person-
years of patients at risk).  Prevalence was defined as the number of existing cases when 
the study commenced plus the incident cases (numerator – new and old 
cases/denominator – total number of records).  During this period of time there were 
41,386 incident cases of type 2 diabetes.  Prevalence of type 2 diabetes increased from 
2.47% to 3.9% between 1996-2005.  Incidence of type 2 diabetes increased from 2.60 to 
4.31 per 1000 person-years between 1996 and 2005 (age and sex standardised).  The 
change in incidence was less in men (63% increase) than women (69% increase).   
 
Obesity associated with incident cases of type 2 diabetes rose from 46% in 1996 to 56% 
in 2005.  The researchers suspected much of the increase in type 2 diabetes was 
therefore due to obesity.  This finding is particularly concerning when considered with 
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the global estimates described previously,
10
 which leads to the likely conclusion that the 
projected worldwide prevalence in 2030 will indeed be much higher than 366 million.    
 
In the course of this research both ethnicity and deprivation emerged early on as key 
determinants for increasing risk of type 2 diabetes.  This was consistent with existing 
evidence on those with established disease.  For those diagnosed with type 2 diabetes 
wide social and ethnic differences in prevalence are well recognised.  Deprived 
populations have higher rates of type 2 diabetes
13
 likely linked to higher rates of obesity 
and lower income in these population groups.  South Asians and Black groups have a 
rate of type 2 diabetes six and three times greater than the White population 
respectively
13
 and the most affluent fifth of the whole population (<55 years) have half 
the prevalence of the most deprived fifth.
14
  The reasons for ethnic associations are 
complex and not fully understood, but evidence suggests South Asians may be more 
prone to fat deposition patterns that predispose to type 2 diabetes
15-17
, and ethnic 
minorities in general are less likely to exercise.
13
   
 
The burden of type 2 diabetes related morbidity and mortality is considerable for both 
patients and local and national health economies.  Expenditure on diabetes in the 
National Health Service (NHS) may be as high as 10% of total yearly budget
18
 and 10-
20% of patients in hospital have diabetes (this cohort also has disproportionately longer 
in-patient episodes and increased costs).
11
  As many as 50% of people with type 2 
diabetes have complications at diagnosis,
19
 which may have been detectable up to seven 
years previously, and the onset of type 2 diabetes as long as twelve years prior to formal 
diagnosis.
20
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East London 
 
The cross-sectional analysis and geospatial mapping described later in this thesis used 
data, as stated before, from three inner city boroughs and one city district (which is 
grouped with one of the boroughs): Tower Hamlets, Newham, and City & Hackney.  
Using data from the Quality Outcomes Framework (a remuneration programme for all 
general practitioners (GPs) based on clinical performance) overall numbers of registered 
persons over 16 with diabetes has been estimated to be 45,688, which is approximately 
6% of the population (Tower Hamlets 13,770; Newham 18,467; City & Hackney 
13,451).
21
  Quantifying prevalence of type 2 diabetes is problematic due to undiagnosed 
disease, uncertain population sizes, high population mobility and inaccuracies in disease 
recording and registration data.  Local data from the Clinical Effectiveness Group 
(CEG) estimate a standardised prevalence of approximately 7% (10% in the South 
Asian ethnic group).  Diabetes registers have been steadily increasing.  In 2010 the 
register size was 40,866.  These changes are more marked in Tower Hamlets and 
Newham.
22
   
 
The Borough of Newham has the highest prevalence of diabetes of all boroughs in 
London.  Increasing rates in children and young people are thought to be linked to the 
increase in obesity (Newham has the second highest rates of obesity for reception year 
children in England).  The non-white ethnic groups are at increased risk.  Doctor-
diagnosed diabetes was 2.5-5 times greater than the general population for Black 
Caribbean and South Asian groups.  It is common in Newham for diabetes to be thought 
of as a normal part of life, and it is of concern that this may have affected the 
population’s view of the serious health consequences.23  
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The City of London & the Borough of Hackney has the lowest prevalence of diabetes in 
East London.  Yet, the standardised rate of registered persons with diabetes on the 
register has increased from 4.2% - 5.4% between 2004-2010, compared to 5.9% - 7.4% 
for Newham and 5.9% - 7.2% for Tower Hamlets.
22
  It is also recognized locally that 
there is a large undiagnosed population.  In the over 40 age group prevalence is 11.1%, 
and GP level prevalence in this group vary from 4.7% to 20.3%.
24
   
 
Late diagnosis and co-morbidities feature strongly as characteristics of the existing 
diabetic population in Tower Hamlets.  In 2006, Picker Institute Europe surveyed 
people with diabetes from ten general practices.
25
  Out of 856 people selected at random 
from the practices, 340 people returned completed surveys.  The poor response rate 
means caution needs to be taken with the findings.  Eleven percent reported type 1 
diabetes, 53% type 2.  Findings indicated that for some people diagnosis was made late 
– 16% started insulin within three months of diagnosis.  The majority (40%) were 
middle aged (40-59 years), and 77% were on medications for other conditions.  High 
prevalence overall in Tower Hamlets is partly attributed to the increased risk of disease 
in South Asian communities (who make up 30% of the population).  Large increases are 
expected overall, with an average prevalence of 10.1% expected by 2030.
26
  
 
Conclusion 
 
Diabetes is increasing exponentially: globally, in the UK, and locally in East London.  
Estimates are fraught with various difficulties, including: [a] coding being unable to 
distinguish between different types of diabetes, [b] under-estimations due to other 
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unaccounted for factors, [c] people with undiagnosed disease not being accurately 
accounted for (known unknowns), [d] uncertain future population sizes, and [e] poor 
response rates in survey data potentially over or underestimating findings.  Yet, 
increases in prevalence and incidence are undisputed and the contribution of obesity, 
lack of physical activity, ethnicity and deprivation are known to be major risk factors.   
 
These findings from the research literature offer strong support for initiatives aimed at 
preventing diabetes.  In the next section, I will describe how I approached this by 
reviewing scoring systems designed to identify those at high risk of developing type 2 
diabetes in the future.   
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SECTION 2: Systematic Review of Diabetes Risk Scores 
Chapter 3: Background, Aims and Methods 
 
This section presents a systematic review of type 2 diabetes risk models and scores.  
The background section of this chapter describes the history of diabetes risk scores, and 
the underlying science.  I then outline the aims of the systematic review including 
detailed methodology, and changes that occurred during the course of the study.   
 
Background 
 
Risk prediction is a complex science concerned with estimating the likelihood of any 
individual (or population) developing an outcome (usually a disease) of interest, based 
on a series of known risk factors.  Epidemiologists and statisticians have been striving 
to produce weighted models and scores that are perceived as sufficiently simple, 
plausible, affordable and implementable to be adopted widely in clinical practice.
27 28
  
 
Risk models and scores first emerged prominently in relation to cardiovascular disease, 
and these are widely used in clinical and public health practice.  In the UK for example, 
all general practice electronic patient record systems offer the facility to calculate the 
‘Framingham score’ or ‘QRisk score’, a patient’s 10-year risk of a cardiovascular event.  
These cardiovascular disease risk scores feature in many guidelines and decision 
pathways (such as the cut-off for statin therapy
29
) and general practitioners receive 
financial rewards for calculating it.
30
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Researchers in England, America and Finland have led the development of type 2 
diabetes risk models and scores.  Presented below is a brief description of three early 
models and scores, one from each of these countries, to set the scene for a more detailed 
discussion of the individual steps in creating a risk score.    
 
The Cambridge Score
31
 is well known and widely cited in the literature.  Developed by 
Griffin et al. in 2000, it used cross-sectional data to derive a risk score.  These 
researchers determined that age, gender, body mass index, steroid and antihypertensive 
medication, family and smoking history were most predictive of risk in an English 
population aged 40-64 years.  This was also one of the first studies that showed that 
information routinely held on GP databases could predict type 2 diabetes.  The risk 
score was developed retrospectively from two separate cross-sectional research 
populations.  First, from general practices in Cambridge (Ely study, population size 
4,922).  And, second, from a population of registered people from 41 general practices 
in Wessex (population size 455,566).  In total 1077 randomly selected people from the 
Ely study without diabetes aged 40-64 completed a standard OGTT, lifestyle 
questionnaire and clinical measurements.  All new diagnoses of type 2 diabetes (48) 
were recorded.  The Ely study group was randomly divided in two, one half to derive 
the risk score and the other half to internally validate (see definition in Table 1) the 
score.  To derive the risk score half the group of newly diagnosed type 2 diabetics in age 
groups 40-64 years (25 cases) were added to half of the newly diagnosed type 2 
diabetics in age groups 40-64 years (101 cases) from the Wessex group.  This formed a 
larger group for deriving the score and their variables were used in a logistic regression 
with risk factors being retained if statistically significant (p<0.05).  This study 
illustrated the complex methodology and study designs which would become common 
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in this field, and the Cambridge Score has heavily influenced future researchers deriving 
and validating risk models and scores.   
 
The San Antonio Score
32
 created in 2002 was one of the first scores to incorporate 
biochemical indices.  Medical history, Body Mass Index (BMI), blood pressure, OGTT, 
fasting serum cholesterol and triglyceride levels were obtained retrospectively from the 
San Antonio Heart Study.  Random selection from this cohort resulted in a population 
of 1,791 Mexican Americans and 1,112 non-Hispanic Whites without known type 2 
diabetes from a possible population of 5,158 (which was based on randomly selected 
households representing different socio-economic and ethnic groups, age range 25-
64years).  A full model and a simplified model were developed and comparisons 
between scores for identifying type 2 diabetes performed - both including and excluding 
the OGTT.  The cohort was followed for 7.5 years and 204 Mexican Americans and 65 
non-Hispanic Whites developed type 2 diabetes.  The clinical model without OGTT 
consisted of: age, sex, ethnicity, fasting glucose level, systolic blood pressure, high 
density lipoprotein (HDL) cholesterol level, BMI and family history of diabetes.  This 
study was one of the first to use many different combinations of variables and compare 
their statistical properties.  
 
The Finnish Risk Score
33
 (known as FINDRISC) published in 2003 is currently the 
most cited diabetes risk score.   It used the National Population Register in Finland in 
1987 to create a score based on a random sample of 4,435 people (aged 35-64 years) 
without a history of using diabetes medication.  Individuals were followed for ten years 
to determine who would develop drug treated diabetes by using the Social Insurance 
Institution drug register up to 1997.  182 people developed incident type 2 diabetes.  A 
31 
 
second sample was taken from the National Population Register from 1992 and used as 
a validation cohort.  The final score consisted of: age, BMI, waist circumference, blood 
pressure medication, history of high blood glucose, physical activity and various foods 
eaten.  The Finnish risk score set various precedents, including making use of wide 
ranging data-sets, making assumptions and using proxies for diagnosis of type 2 
diabetes, and toggling variables to develop ‘full’ and ‘concise’ models.   
 
These three early risk scores were important in the development of this field as they 
established a number of methodological approaches as ‘standard’ in the literature, which 
were to heavily influence future researchers, including: [a] complex study designs 
which were unlikely to be easily repeatable by other researchers, although principles 
could be applied, [b] testing various models with different variables, [c] innovatively 
using various data sources to identify people without diabetes, and [d] using different 
methods for confirming diagnosis of type 2 diabetes.   
 
This brief review of three early models demonstrates that diabetes risk scores, which 
predict risk of developing future disease, can broadly be considered as prognostic 
models and should broadly be subject to the same methodological principles
34-37
, 
although the key difference is they are considering risk of future disease as opposed to 
outcomes of existing pathology.  From an initial literature review of 29 papers and 
discussion with various experts in the field, it became clear that there were several steps 
involved in creating, testing and using a type 2 diabetes risk score.  These six steps are 
shown in Table 1, and then discussed in detail as part of the context for the formal 
systematic review.   
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Six steps of type 2 diabetes 
risk score development 
Definition 
Derivation Creating a diabetes risk score composed of various 
individual risk factor components 
Discrimination Distinguishes reliably between people who will 
develop the condition and people who will not 
Calibration Assessing over time whether what is initially 
predicted transpires to be close to what is actually 
observed 
Validation Running the score on a different population of people 
to test its performance 
Reclassification Comparing different risk scores with different 
variables around given thresholds 
Application Using the score in real life on an actual population 
e.g. in a general practice surgery 
 Table 1: Development of a diabetes risk score 
 
The gold standard approach for deriving a type 2 diabetes risk score is to take a large, 
age-defined, non-diabetic population cohort, measure baseline risk factors, and follow 
the cohort for a sufficiently long time period to see which individuals go on to develop 
diabetes.
37
  An example of a cohort used for this purpose is the Framingham heart study, 
which started in 1948, and is a well known example of a cohort study that followed a 
population over several generations to study risk factors for cardiovascular disease 
(CVD).
38
  Assessing risk of type 2 diabetes from existing research populations, like 
Framingham, or from routinely collected data, has been particularly attractive as this 
approach uses readily obtainable information without the need for de novo data 
collection or for invasive procedures such as blood glucose testing.   
 
Re-testing for type 2 diabetes at the end of the cohort should ideally use the same test as 
at baseline.  Follow-up rate should be as high as possible.  The final sample therefore 
has two principle groups: those with and without type 2 diabetes, all with a series of 
measured risk factors at baseline.  This provides a basic incidence statistic over time.  A 
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regression analysis of risk factors determines which were statistically correlated with 
disease, allowing the creation of a weighted model.   
 
An example of an approach to score derivation can be worked through by considering a 
risk score devised in 2006 in Thailand based on a 12 year cohort of people from 1985 
and 1997.
39
  The initial cohort comprised 3,499 workers aged over 35 years from an 
electric plant.  The initial cohort had been created prospectively to study vascular risk 
factors contributing to cardiovascular mortality.  Multiple baseline measurements were 
collected including a fasting plasma glucose (FPG) and OGTT.  This allowed exclusion 
of people with type 2 diabetes based on the American Diabetes Association (ADA) 
definition of type 2 diabetes from the FPG and OGTT results.  An additional exclusion 
criteria of a previous known diagnosis of diabetes was also used.  Within the baseline 
measurements were multiple risk factors for developing type 2 diabetes.  The 
researchers chose to analyse: sex, age, BMI, waist circumference, hypertension, family 
history, smoking, alcohol consumption, IFG, impaired glucose tolerance (IGT) and 
serum cholesterol.  The cohort began with 3,254 people and 2,667 (82%) were present 
at the end of the study.  At the 12 year point 361 had been diagnosed with type 2 
diabetes defined by: FPG, OGTT, prescription of diabetes medication or diagnosis.  
Incidence of diabetes was calculated as 13.5% in this cohort over 12 years.  The 
differences in the values of the risk factors between the 361 with type 2 diabetes and the 
2,316 without type 2 diabetes were compared using a logistic regression with diagnosis 
of type 2 diabetes as the dependent variable and each of the risk factors as independent 
variables.  P-values were displayed for each risk factor indicating whether the difference 
was statistically significant.    Odds ratios for predicting diagnosis of type 2 diabetes at 
12 years with 95% confidence intervals for each risk factor measured at inception was 
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calculated.  Certain risk factors were significant and these were included in the final 
score.  The log of the odds ratios from these factors was presented as a beta-coefficient 
and a numerical score as an integer attached to each.  The final score was out of 17 as 
shown in Table 2.  A score of 17 equated with a 100% cumulative incidence of diabetes 
at year 12.   
 
Risk factor  Coefficient  Diabetes risk score 
Age (years)   
34–39  0 
40–44  -0.07 0 
45–49  0.27 1 
≥50  0.60 2 
Sex   
Women  0 
Men 0.44 2 
BMI (kg/m
2
)   
<23 0  0 
≥23 but <27.5  0.69 3 
≥27.5  1.24 5 
Waist circumference (cm)   
<90 in men, <80 women  0 
≥90 in men,  ≥80 in women 0.56 2 
Hypertension   
No  0 
Yes 0.64 2 
History of diabetes in parent 
or sibling 
  
No  0 
Yes  1.08 4 
Table 2: Example of creation of diabetes risk score 
Reproduced from Aekplakorn W, Bunnag P, Woodward M et al. A risk score for 
predicting incident diabetes in the Thai population. Diabetes Care 2006;29(8):1872-77.   
 
The coefficients in Table 2 above represent what I have described broadly as the 
underlying model, which in some studies is presented as a more complex mathematical 
equation.  This is linked, but separate from the risk score, which is generally presented 
as an integer derived from the coefficient.  I have often used the phrase ‘type 2 diabetes 
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risk model or score’ reflecting the sequence of derivation events.  A risk score based on 
regression analysis has an underlying model, but not all models have been converted to 
risk scores.   
 
Current cohort derived type 2 diabetes risk models and scores have generally been 
derived from retrospective research on population cohorts which were assembled for 
another purpose.  This includes risk models and scores which claim to have been 
derived from ‘prospective’ cohorts.  The term ‘prospective’ is accurate insofar as the 
inception cohort was followed prospectively (for example to look at the development of 
some other disease such as cardiovascular events), but it is incorrect insofar as the study 
of diabetes risk is strictly retrospective.  The ‘prospective’ cohort is typically studied at 
a future point in time (e.g. a diabetes risk researcher in 2010 may begin to study a 
cohort assembled and studied between 1990-2000), thus achieving ‘retrospective 
research of a prospective cohort’.  This opens up the potential for a series of biases, 
including: [a] the initial population has a degree of selection bias (the cohort was 
assembled for a different research purpose), [b] lack of sensitivity to diagnose type 2 
diabetes as cohorts may have been designed to primarily detect different outcomes, [c] 
being restricted to a set of pre-defined risk factors selected by different researchers for a 
different purpose, and [d] the instruments used to measure risk factors (such as lifestyle 
questionnaires) may not have been specifically validated for type 2 diabetes, introducing 
a possible measurement bias.  In addition to possible biases, other limitations are 
inherent.  For example, specific age ranges are often used for cohort studies (e.g. 35-65 
years) and those using the cohort for type 2 diabetes risk score generation later are 
therefore limited to this age range.   
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Considerable variability also exists in methodologies employed to derive a diabetes risk 
model or score from a cohort study.  The original research team will typically have 
recruited participants at a start date or over a fixed period of time.  To derive the risk 
model or score for type 2 diabetes a series of exclusion criteria are usually applied to 
entrants, most importantly removing all persons with known diabetes.  Other exclusion 
categories include pregnant women (since development of gestational diabetes would 
influence results), and children and adolescents (since type 2 diabetes is less common in 
these groups).  Baseline data are often collected at cohort inception.  These include 
variables such as age, gender, ethnicity, medication history and BMI.  Tests for existing 
diabetes, such as OGTT or diabetes medication prescriptions are sometimes used to 
exclude participants with diabetes and confirm that undiagnosed diabetes is not present 
within the cohort.  The cohort of individuals is followed for a period of time, typically 
between 3-15 years.  Re-measurement of some or all of the baseline variables takes 
place at points throughout the study and/or at the end of the study period.  At the 
intervals and end point of the study a number of participants will have developed 
diabetes, a basic incidence statistic.  As with the baseline tests, the diagnosis of diabetes 
may be confirmed in a variety of ways between different studies.  Box 1 below shows 
some of the ways that a diagnosis of type 2 diabetes is assumed at inception and at 
various points throughout cohort studies.   
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FPG 
OGTT 
Death certificates 
Physician diagnosis 
Self-reported diagnosis 
Medication registers 
HbA1c level 
International Classification of Disease (ICD) code 
Dietary treatment 
Medical records 
Electronic records 
Box 1: Sources of diagnostic criteria for diabetes in risk score studies 
 
Multiple diagnostic criteria present numerous problems, including inaccurate diagnoses 
and lack of comparability between studies.   Additionally, many of these criteria rely on 
coding which often has high levels of associated errors, and using a different diagnostic 
test at the beginning and end of a cohort may produce inconsistent prevalence estimates 
and threaten both accuracy and precision.   
 
Once a diabetes risk score has been derived, an assessment of how reliably it predicts 
those who go on to develop diabetes needs to be made.  One of the most common 
measures used is discrimination.  This is often measured as sensitivity and specificity, 
or a function of both.  High sensitivity in this context refers to the likelihood that the 
risk score predicts who will develop diabetes.  For example, a test with 75% sensitivity 
correctly identifies 75% of those who will develop diabetes, and misses 25%, 
incorrectly classifying them as negatives.  The term ‘specific’ in this context means that 
the risk score reliably picks up those who will not go on to develop diabetes e.g. a test 
with 75% specificity correctly identifies 75% of the persons who will not develop 
diabetes, and misses 25%, incorrectly classifying them as positives.   
38 
 
Sensitivity and specificity of a risk score can be combined to produce an Area under a 
Receiver Operating Curve (AUROC).  This is a graphical display of these two measures 
and helps visualise discriminatory ability.  On the y-axis sensitivity is plotted versus 1-
specificity on the x-axis.  1-specificity is used as it measures the rate of false positives 
(those who will not get the disease but are falsely classified as positives by the risk 
model or score using that threshold).  Sensitivity is an indication of the true positive 
rate, and so the graphical display allows true positives and false positives to be 
compared.  This creates a curve showing the change in 1-specificity (or false positive 
rate) for increasing sensitivity (or true positive rate).  There is a trade-off between 
sensitivity and specificity and usually the optimum cut-off is the point of the highest 
true positive and lowest false positive rates.  The AUROC can be quantified, known as 
the C-index, a statistic by which different risk models and their discriminatory power 
may be compared.   
 
A cut-off score is usually determined which picks up the highest number of true 
positives and the lowest number of false positives.  This is unlikely to be the highest 
score, although it could be.  It may be that a score of e.g. 17/20 has a sensitivity of 75% 
and a specificity of 65%; however a score of 12/20 has a sensitivity of 95%, but 
specificity of 40%.  Research studies often tabulate these results and show the cut-off 
score that has the highest sensitivity and specificity, or represents it as the AUROC.   
 
If significant risk factors are missed out of a score (as may happen systematically during 
‘retrospective research of a prospective cohort’), the score will produce a consistently 
biased result – either under or over estimating low or high risk.  The example of 
ethnicity as a known significant risk factor for type 2 diabetes highlights this problem.  
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In a population of entirely White ethnicity the variables age, gender, BMI, waist 
circumference, hypertension, and history of diabetes in parent or sibling will predict risk 
uninfluenced by ethnicity as a risk factor.  The same would be true in an entirely South 
Asian population, because relative to each other the risk is the same, but overall the risk 
would be underestimated as it did not factor in the increased risk due to South Asian 
ethnicity.  However, this would not be reflected in the discrimination statistics.  In 
practice, many populations are heterogeneous with respect to ethnicity.  For example, in 
a population with 20% South Asian ethnicity and 80% White ethnicity the score would 
perform adequately for the White population but would underestimate the risk for the 
South Asian population.  As ethnicity would be unknown, as it was not a measured 
variable, this would mean a poorer result for those truly at high risk of developing type 
2 diabetes i.e. some South Asian people would falsely be classified at lower risk when 
they were in fact at higher risk.  In this example the larger the South Asian group the 
more inaccurate the result at a population level.  The reason for this would not become 
clear until ethnicity was added as a variable.   
 
Calibration is an essential statistic to accompany discrimination and is a further measure 
of predictive power.  It assesses whether what is initially predicted transpires to be close 
to what is actually observed over time.  This is often presented as an observed to 
predicted ratio or a statistic which describes this such as the Hosmer–Lemeshow test or 
Brier score.  By definition this has to occur over a real period of time, and this period of 
time has to be clinically meaningful.  Therefore, an observed to predicted ratio of 
disease occurrence for type 2 diabetes should only be applied to a study which covers a 
period of time that will allow type 2 diabetes to start occurring in reasonable numbers 
within the population in question.  This is also dependent on age structure; older 
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populations being more likely to have higher disease occurrence rates over any period 
of time.  There are no hard and fast rules to govern study length, but given that diabetics 
should have been excluded via diagnostic testing at inception, it is not unreasonable to 
suggest that four years should be a minimum study period (based on type 2 diabetes 
complications being detectable 4-7 years prior to diagnosis
20
).  By definition only 
longitudinal cohort derived risk models and scores can be calibrated.   
 
Validating a risk score refers to using the score on a different population of people to 
test its performance, usually in terms of discrimination and calibration, but this also 
offers an opportunity to assess usability in a different context.  Validation can be done 
either internally (by splitting the original sample, developing the score on one part and 
testing it on another), temporally (re-running the score on the same or a similar sample 
after a time period), or externally (running the score on a new population with similar 
but not identical characteristics from the one on which it was developed).
34 37
  External 
validation on a separate cohort with demographic differences to the original population 
is the gold standard to assess whether a model can be used accurately outside of the 
population it was developed on.   
 
Comparison of discrimination between different models (especially those that have 
added a ‘new’ variable) is common in research deriving and validating type 2 diabetes 
risk scores.  To markedly improve already adequate discrimination in a model of basic 
risk factors (such as age, sex, and ethnicity) ‘new’ variables have to demonstrate 
independent and significant links to risk of type 2 diabetes.
40
  Yet, this alone does not 
confer a better model in clinical practice, particularly where a threshold may exist for a 
change in clinical management.  More important is the performance of the model at 
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different thresholds.
41
  For example, locally in East London if an individual has a 
greater than 20% risk of cardiovascular disease using QRisk
42
 during the NHS Health 
Checks programme
43
 in general practice, this triggers further clinical management.  At a 
population level the proportion who fall just above and below 20% risk become 
significant, especially if the intervention (or lack of) is costly e.g. an invasive 
investigation or prescribing medication, or missing those at high risk with consequent 
long term prognostic implications.  This problem has given rise to the concept of 
reclassification (performance around a pre-defined threshold
44
) and accompanying 
statistical tests, including the reclassification calibration statistic.
45
  This is derived from 
the Hosmer–Lemeshow test and contrasts observed to expected results at various 
thresholds.  Different risk scores with different variables can be compared using this 
technique.  Net reclassification improvement compares risk reclassification and 
tabulates positive and negative change around given thresholds.
45
  This can reveal large 
changes in who falls above and below the threshold for clinical management, even if the 
change in discrimination overall is small.
40
   
 
Caution should be exercised when extrapolating a risk model or score developed in one 
population or setting to a different one (e.g. secondary to primary care, adults to 
children or one ethnic group to another).
36
   Using a score which has been derived from 
a demographically different population will likely result in poorer performance in a new 
population, unless the majority of the most significant risk factors for that population 
(e.g. ethnicity and deprivation) are included in the score.  Ideally there would be a 
unique risk score for each population.  However, in most cases this is impractical and 
expensive, and so a best-fit model needs to be found, based on the performance tests 
described above, and an assessment of usability.  On this latter point this type of 
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qualitative assessment has been done infrequently, and therefore became a major focus 
of the systematic review.   
 
Cohort versus cross-sectional designs for diabetes risk scores 
 
In the course of writing this thesis and carrying out the systematic review, I encountered 
a different, but commonly used approach to develop a type 2 diabetes risk model or 
score by using data from a cross-sectional survey.  Researchers applying this approach 
have generally started with a population at one point in time who are tested for type 2 
diabetes and have certain clinical variables measured.  This splits the population into 
those with and without current disease.  A regression analysis is applied, clinical 
variables weighted, an equation created, a score derived, and performance assessed.   
 
This approach has several problems.  Those with type 2 diabetes have not been studied 
from the point of being healthy subjects to developing disease.  The measurement of 
clinical variables are not truly risk factors, they are instead disease characteristics.  This 
makes temporal association impossible i.e. is the measured variable a risk for 
developing disease or is it a consequence of pathology – under or over estimation of the 
significance of any given disease characteristic is likely.  Discrimination describes the 
ability of the model to detect current disease and calibration is not possible as there is 
no observed to expected ratio.  Figure 1 pictorially represents the main differences.   
 
43 
 
 
Figure 1: Cohort versus cross-sectional design for deriving a risk score 
 
A further problem is the conflation of incidence and prevalence.  Incidence is defined as 
the number of new cases of disease over a specified period of time.  Prevalence refers to 
the total number of cases in any one population at a given point in time.  Using 
prevalence data to predict incidence is only valid in very limited circumstances.  For 
example, in acute infectious disease outbreaks of short duration (e.g. Norovirus) 
prevalence and incidence are closely correlated as the disease in question has low 
background rates in any one population and has a short duration of infection.  However, 
for chronic diseases, using prevalence data (the cross-sectional approach) to estimate 
incidence is problematic.   
 
Though prospective longitudinal designs in specially assembled cohorts are expensive, 
difficult and time-consuming to execute, cross-sectional designs in which risk factors 
are measured in a population including both diabetic and non-diabetic individuals are 
methodologically inferior.   
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Implications of the literature for further research 
 
It is often proposed that risk scores and other prognostic models should be subject to 
‘impact studies’ – that is, studies of the extent to which the score is actually used and 
leads to improved outcomes.  Whilst most authors emphasise quantitative evaluation of 
impact e.g. via cluster randomised controlled trials,
36
 much might also be learnt from 
qualitative studies of the process of using the risk score, either alone or as an adjunct to 
experimental trials.  One such methodology is realist evaluation, which considers the 
interplay between context, mechanism (how the intervention is perceived and taken up 
by practitioners) and outcome.
46
  In practice, however, neither quantitative nor 
qualitative studies of impact are common in the assessment of risk models and scores.
36
   
 
It has been suggested elsewhere that appraisal of risk prediction models have three core 
areas.
41 44
  First, the context for use of the risk prediction model, including the disease of 
interest, the population that the model will be applied to, and the evidence base that 
changing risk is possible.  Second, the actual appraisal of the performance of the model, 
including discrimination, calibration, reclassification and validation, and an assessment 
of the quality of the underlying data.  And, third, implementation in real life, including 
costs, ethics, and training and prioritisation considerations.
41
   
 
Background reading and a basic literature review revealed that whilst there were 
multiple models and scores for assessing risk of developing type 2 diabetes, none were 
in routine use in the UK, in general practice or public health.  There was also no 
systematic review in the academic literature, despite many different models being 
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available.  I thought this presented a confusing picture for both GPs and public health 
specialists, who would be potentially faced with a very complex literature, multiple 
different methodologies, and probably very few studies of use in real life.  In view of 
this situation I wanted to comprehensively determine the performance and impact of 
risk models and scores for predicting type 2 diabetes in adults.   
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Aims of the systematic review 
 
In this systematic review of type 2 diabetes risk models and scores the aim was to 
inform the selection and implementation of diabetes risk models and scores.   
 
The research question for this component of the thesis was:  
 
What is the performance and impact of risk models and scores for predicting type 2 
diabetes in adults?  
 
Hence, I was particularly interested in highlighting the characteristics of a risk model or 
score which would (if appropriate) increase its adoption and use in practice.  To that 
end, I sought along with other members of the review team, comprising Greenhalgh, 
Dent, Meads and Mathur to review the literature on development, validation and use of 
diabetes risk models and scores in different contexts and settings, using [a] quantitative 
data on demographics of populations and statistical properties of models and scores, and 
[b] qualitative data on how models and scores were perceived and used by practitioners, 
policymakers and others in a range of contexts and systems.  We decided given the 
methodological problems with cross-sectional models and scores, as described 
previously, to base the systematic review on cohort studies only, although this decision 
was not taken initially and evolved as the review progressed.   
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Objectives 
 
1. To systematically review known type 2 diabetes risk models and scores for 
adults. 
2. To analyse the demography of the populations from which the models and 
scores were derived. 
3. To analyse the demography of the populations on which they were validated. 
4. To analyse the final components of the models and scores and their contribution 
to overall risk. 
5. To compare the discrimination and calibration statistics used for quantifying 
risk. 
6. If possible and valid, to perform a meta-analysis with specialist statistical 
support.   
7. To review qualitatively the purpose of the models and scores and their use in 
clinical and public health practice.   
 
Methods 
 
Below, I describe the methodology and study protocol.  A tabulated version of the study 
protocol and MOOSE (meta-analysis of observational studies) checklist were submitted 
to the British Medical Journal (BMJ) along with the manuscript of the systematic 
review.  These two documents can be found in Appendix 1 and 2 respectively.   
 
A scoping search was undertaken in January 2011, focusing mainly on existing well 
known type 2 diabetes models and scores recommended by experts and contextual 
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background material.  The yield of 29 papers from this search was used to develop the 
protocol for the review, including search terms, and inclusion and exclusion criteria.   
 
An information scientist, Helen Elwell (HE), a librarian at the British Medical 
Association Library, helped design a search strategy. She was assisted by Catherine 
Meads (CM) and myself (DN, principal investigator).  Relevant guidance in Systematic 
Reviews: Centre for Reviews and Dissemination guidance for undertaking reviews in 
health care, and Systematic Reviews to Support Evidence-Based Medicine was drawn on 
to identify any relevant studies of type 2 diabetes risk models and scores.
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  I 
implemented the final search strategy, which was double-checked by both HE and CM.  
The final search was undertaken on 11
th
 February 2011.   
 
The key words for the literature search were: predict, screen, risk, score, [type 2] 
diabetes, model, regression, risk assessment, risk factor, calculator, analysis, sensitivity 
and specificity, ROC and odds ratio.  A decision was made to search titles and abstracts 
in MEDLINE (including recent un-indexed papers listed in Pre-MEDLINE), EMBASE 
and the Cochrane Library with no language or date restrictions.   
 
The search of Medline searched for type 2 diabetes in the thesaurus and also in free text.  
Relevant statistical terms in the thesaurus search were combined with the word risk 
adjacent (within three words) of other key words in the search.  The relevant statistical 
terms and the risk search were combined with the type 2 diabetes search.  In order to 
narrow the search further the function to focus on diabetes or prediabetic state as the 
main focus of the article was chosen.  This result was incorporated to produce the final 
result.  This resulted in 6,169 papers.  The search of EMBASE searched for type 2 
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diabetes in the thesaurus and also in free text.  Relevant statistical terms in the thesaurus 
search were combined with the word risk adjacent (within three words) of other key 
words in the search.  The relevant statistical terms and the risk search were combined 
with the type two diabetes search.  In order to narrow the search further the function to 
focus on non insulin dependent diabetes mellitus as the main focus of the article was 
chosen.  This result was incorporated to produce the final result.  This resulted in 6,947 
papers.  The text word strategy was used only for unindexed MEDLINE papers 
resulting in 524 papers.  A MESH search only was performed in the Cochrane Library 
for type 2 diabetes mellitus and risk resulting in 716 titles.  Details of the exact search 
strategies executed can be found in Appendix 3.   
 
From the search strategy 14,356 titles were moved into the electronic reference package 
ENDNOTE and duplicates automatically removed.  This resulted in a total of 10,275 
titles.  Some duplicates remained which ENDNOTE was not able to discriminate 
between and these were removed manually resulting in 8,864 titles.   
 
Two independent researchers (DN and Rohini Mathur (RM)) independently scanned all 
8,864 titles and if it was suspected that the title represented a paper which met the 
inclusion and exclusion criteria, the abstracts were reviewed.   
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Initial inclusion criteria 
Study design:  Any study deriving or validating a risk model or score for type 2 
diabetes.   
Population:  Adults over age 18 with no upper age limit.   
Intervention: Developing models or scoring systems based on type 2 diabetes risk 
factors to predict temporal risk of type 2 diabetes in adults and/or validation of a type 2 
diabetes risk model or score.   
Outcomes: Any relevant predictive outcomes, including discrimination and calibration.   
 
Initial exclusion criteria 
1. Studies which had not finished recruiting. 
2. Studies examining one or more single risk factors that had not been linked 
together to form a model or scoring system.  
3. Screening and early detection studies. 
4. Models predicting genetic mutations rather than type 2 diabetes. 
5. Case series. 
6. Studies carried out on animals. 
 
Title scanning was finished in March 2011.  DN marked 141 titles as potentially 
meeting inclusion criteria and RM marked 124 titles.  Where possible, abstracts were 
reviewed, if not, full papers were requested.  Following available abstract review DN 
requested 79 full papers for further review and RM 55 full papers.  These were 
combined and 38 duplicates removed resulting in 96 full papers.  Owing to the 
methodologically complex nature of this dataset DN categorised these 96 papers within 
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an Excel spreadsheet under the following headings, as it was becoming apparent that the 
initial inclusion and exclusion criteria were not fully adequate and that there were major 
methodological problems in the literature: 
 
1. First author 
2. Journal 
3. Year of publication 
4. Country of origin of research population 
5. Language 
6. Brief context 
7. Research performed on adults without preselected diseases or risks– yes/no  
8. Derived a risk score – yes/no 
9. Validated the risk score on a separate population 
10. Type of study – e.g. cross-sectional or cohort 
11. Period of time derivation population studied (years) 
12. Age range of derivation group (years) 
13. Period of time validation population studied (years) 
14. Age range of validation group (years) 
15. Method of confirming diagnosis in derivation group 
16. Method of confirming diagnosis in validation group 
17. Calibration statistics presented 
18. Discrimination statistics used 
19. Validated or compared or used other scores 
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On reviewing this spreadsheet, and after discussion with the project team, the inclusion 
and exclusion criteria were modified as below.  This reduced the number of final papers 
included in the review, but would not have influenced selection of titles, abstracts or full 
papers prior to this stage, as the initial inclusion and exclusion criteria was broader than 
the final criteria.  The main difference was the exclusion of cross-sectional studies as 
these were considered to be less methodologically robust.   
 
Final inclusion criteria 
Study design: Any cohort study which derives and/or validates a type 2 diabetes risk 
model or score.   
Population:  Adults over age 18 with no upper age limit.   
Intervention: Developing models or scoring systems for type 2 diabetes based on 
regression analysis to predict temporal risk of type 2 diabetes in adults and/or validation 
of a type 2 diabetes risk model or score, on a different population.   
Outcomes: Any relevant predictive outcomes, including discrimination and calibration.   
 
Final exclusion criteria 
Study design: Cross-sectional designs, other screening or early detection studies, 
genetic studies or case series. 
Population: Pre-selected populations with existing risk factors or disease, studies on 
under 18s, studies carried out on animals, and studies which have not finished 
recruiting. 
Intervention: Studies examining one or more single risk factors that have not been 
linked together to form a model or scoring system, and studies that applied a known risk 
model or score to a population but did not evaluate its statistical potential.   
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Ten papers out of the 96 full papers were in a non-English language (Persian, Chinese, 
Dutch, German (4), Polish, Hungarian and Spanish).  Although three had no English 
abstract it was obvious to both DN and RM that they were either a commentary, 
editorial or article, and did not contain quantitative data or a risk model or score.  These 
were excluded.  Four further papers were excluded after discussion because the English 
abstract clearly indicated they did not meet the inclusion criteria.  Three were marked 
for translation.   
 
Following independent full paper review, using the final inclusion and exclusion 
criteria, DN reduced the total to 24 full papers and RM to 22.  One paper selected for 
inclusion by RM was excluded after joint discussion; her other 21 choices were within 
DNs final set.  The extra three papers selected for inclusion by DN were included after 
discussion and in particular, revisiting the inclusion criteria.  This resulted in 24 full 
papers.  Therefore 69 out of 96 papers were excluded after full paper review from the 
main literature search, leaving 27 (including 3 marked for translation) remaining.   
 
Full papers from other sources 
 
Seven more papers were added from the initial scoping search, one paper from a Google 
search, and eight papers following a Google citation review of the majority of the 96 
full papers (papers that did not have citation tracking included foreign language papers 
and those that were of limited relevance to diabetes risk models or scores).  DN 
performed these searches alone.  This resulted in 16 further full papers.   
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DN and RM divided the task of reference saturation from key references, which 
included all 43 papers included for data extraction to this point, other papers in the 96 
full papers and also commentaries, editorials, PhD theses and other relevant sources.  
This added three full papers.   
 
In total 46 papers were selected for full data extraction.   
 
Quantitative data extraction 
 
Quantitative data extraction was undertaken under the following headings: 
1. Author 
2. Journal 
3. Year 
4. Country/Context 
5. Language 
6. How many models? 
7. Name of study derived from e.g. Framingham 
8. Name of score e.g. QDScore 
9. Study design 
10. If validation only study where is it derived from? 
11. Reasons for original recruitment 
12. Sample size 
13. Study duration 
14. Year studied from - to 
15. Age 
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16. Gender 
17. Ethnicity 
18. Deprivation 
19. Qualitative descriptor of cohort / sample  
20. Diabetes excluded in inception cohort - yes/no 
21. How diabetes diagnosed at inception 
22. How diabetes diagnosed at intervals +/or completion 
23. Follow-up rate to end of cohort 
24. Prevalence of diabetes at cohort inception 
25. Incidence of diabetes at end of cohort 
26. Risk score components 
27. Sensitivity (of authors preferred cut-off - note rationale) 
28. Specificity (of authors preferred cut-off - note rationale) 
29. How derived cut-off score (s) 
30. AUROC + 95% CI 
31. Positive predictive value (PPV) 
32. Negative predictive value (NPV) 
33. Calibration 
34. Other statistics 
35. Description of internal validation if present 
36. Percentage that would need further testing if classified high risk by authors 
37. Extra notes 
 
Some studies offered numerous different models with different risk factors included in 
each.  It was beyond our capacity to study in detail every one of these models, and often 
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the authors themselves had concluded that, for example, of six models tested one clearly 
outperformed the others. Where studies had tested multiple models or scores with 
minimal difference in the risk factors included, we extracted data from the authors’ 
preferred model(s) or (if no preferences were stated in the paper) the ones judged by 
two researchers to be the most complete or statistically robust.  Our aim was to use 
statistical meta-analysis where appropriate and to present heterogeneous data in 
disaggregated form.   
 
DN did primary data extraction for 23 full papers;  CM did 10 and RM did 9.  RM and 
DN discussed one of the included papers which transpired not to have been peer 
reviewed.  This was then excluded, reducing the total of included papers to 45.  DN 
worked with translators to extract data from the three papers in Persian, Spanish and 
Dutch.   
 
Dr Tom Dent (TD) joined the project team to independently double check all of the 
quantitative data extraction apart from the translated papers.  As the translations were 
done by DN working alongside a GP, medical student or scientist, these papers had 
already been double checked.  TD raised concerns that two further papers did not meet 
the criteria and this was discussed with the entire research team and were excluded.  The 
final number of papers included was therefore 43.   
 
Qualitative data extraction 
 
Along with Professor Trisha Greenhalgh (TG), and drawing on the principles of realist 
review (a relatively new form of systematic literature review which uses mainly 
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qualitative methods to produce insights about the interaction between context, 
mechanism and outcome - explaining instances of both success and failure
49
) the 
following research question was addressed:  
 
What is the relationship between the components of the score, the context in which it 
was intended to be used and the mechanism by which it might improve outcomes for 
patients? 
 
Data was extracted and entered on a spreadsheet under seven headings:  
 
1. Intended users: Authors’ assumptions (if any) about who would use the risk 
score, on which subgroups or populations 
2. Proposed action based on the score result: Authors’ assumptions (if any) on 
what would be offered to people who score above the designated cut-off for high 
risk 
3. Mechanism: Authors’ hypothesised (or implied) mechanism by which use of the 
score might improve outcomes for patients 
4. Descriptor: Authors’ adjectives to describe their risk model or score 
5. Relative advantage: Authors’ claims for how and in what circumstances their 
model or score outperforms previous ones 
6. Concerns: Authors’ stated concerns about their model or score 
7. Real world use, including citation tracking: Actual data in this paper or papers 
citing it on use of the score in the real world 
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TG performed the data extraction.  DN played a supporting role in this part of the 
systematic review (as oppose to leading the quantitative part of the review).  For the 
realist review, DN independently double checked the data extraction from 15 of the 43 
papers, agreed with the findings and added a small amount of additional material.  
Context-mechanism-outcome interactions hypothesised or implied by authors were 
discussed among our research team and these mechanisms were explored further by re-
reading the full sample of papers with all emerging mechanisms in mind.   
 
Impact analysis 
 
We assessed the impact of each risk score in our final sample using three criteria: [a] 
any description in the paper of use of the risk score beyond the population in which it 
was developed and validated, [b] number of citations of the paper in Google Scholar, 
and number of these which described use of the risk score in an impact study (TG did a 
second full citation track of the included papers looking for this specifically), and [c] 
critical appraisal of any impact studies identified on this citation track.  In this phase, we 
were guided by the question:  
 
What is the evidence that this risk score has been used in an intervention which 
improved (or sought to improve) outcomes for individuals at high risk of diabetes? 
 
Prioritising papers for reporting in the published paper 
 
Given the large number of papers and risk models and scores in our final sample, we 
decided for clarity to highlight the seven models or scores most likely to be useful to 
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practising clinicians, public health specialists or lay people.  Adapting Altman et al’s 
quality criteria for risk scores,
37
 the following were used to guide the prioritisation of 
scores for reproduction in a concise and easily accessible table: [a] external validation 
by a separate research team on a different population (generalisability), [b] statistically 
significant calibration, [c] a discrimination greater than 0.70, and [d] 10 or fewer 
components (usability).  External validations frequently altered the original score by 
either: [a] the number of risk factors, [b] categorisation of the risk factor e.g. using a 
different ethnicity, and [c] not stating exactly which risk factors they used from the 
original model or score.  We did not exclude the external validation on this basis as part 
of our prioritisation was linked to impact.  One score which has not yet been externally 
validated was included in the concise table because the review of impact in the 
qualitative part of the review had highlighted it.   
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Chapter 4: Results and Discussion 
Below I describe the main findings of the systematic review.  The full version of this 
systematic review, already published in the BMJ, can be found in this thesis as 
Appendix 4.  Only one table has been reproduced in the main body of the thesis.  All 
other tables can be found in Appendix 4 and are referred to in the text in this section for 
reference purposes only.   
 
Results 
Figure 2 shows the flow of papers through the study.   
 
Figure 2: Flow of studies through the systematic review 
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In summary, 115 papers were analysed in detail to produce a final sample of 43 - 18 of 
which described development of one or more risk models and/or scores;
32 50-66
 17 
described external validation of one or more risk models and/or scores on a new 
population(s);
67-83
 and eight did both.
33 39 84-89
  In all, the 43 papers described 145 
models, from which we selected 94 for full data extraction (the other 51 were minimally 
different, were not the authors’ preferred model, or lacked detail or statistical 
robustness).  This sample of 94 included 55 derivations of risk-predicting models on a 
base population and 39 external validations of 14 different risk models or scores on new 
populations.  Studies were published between 1993 and 2011, but most have appeared 
in the past three years. [Figure 3]  Indeed, even given that weaker cross-sectional 
designs had been excluded, findings suggested that new diabetes risk models and scores 
were currently being published at a rate of approximately one every three weeks.   
 
 
Figure 3: Publication of diabetes risk models and scores 1990-2010. 
Eleven new risk models and scores had been published in the first five months of 2011 
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Appendix 4 (Table 1) gives full details of the studies in the sample, including the origin 
of the study, setting, population, methodological approach, duration, and how diabetes 
was diagnosed.  In sum, the studies were highly heterogeneous. Models were developed 
and validated in 17 countries representing six continents (30 in Europe, 25 in North 
America, 21 in Asia, 8 in Australasia, 8 in the Middle East, one in South America and 
one in Africa).   
 
Comparisons across studies were problematic owing to heterogeneity of data and highly 
variable methodology, presentation techniques and missing data.  Cohorts ranged in size 
from 399 to 2.54 million.  The same datasets were often used in several different models 
in the same paper.  Ten research populations were used more than once in different 
papers.
32 51 56 57 59 61-63 65-71 78 80-84 87 88
  In total, risk models were tested on 6.88 million 
participants, although this figure includes multiple tests on the same datasets.  
Participants aged 18 to 98 years were studied for periods ranging from 3.15 to 28 years.  
Completeness of follow-up ranged from 54 to 99% and incidence of diabetes across the 
time periods studied ranged from 1.3 to 20.9%.   
 
None of the risk scores in the sample was developed on a cohort recruited prospectively 
for the purpose of devising a model or score.  Rather, all authors used the more 
pragmatic approach of retrospectively studying a research dataset which had been 
assembled some years previously for a different purpose.  There were 42 studies that 
excluded known diabetes in the inception cohort.  Diagnosis of diabetes at inception and 
completion of cohort was done in different ways including self-report, patient 
questionnaires, clinician diagnosis, electronic code, ICD code, disease or drug registers, 
diabetes medication, dietary treatment, fasting glucose, oral glucose tolerance test, 
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Glycated Haemoglobin A1c (HbA1c), and some studies did not state the method.  Half 
the studies used different diagnostic tests at inception and completion.   
 
One-third of the papers focused almost exclusively on the statistical properties of the 
models or score(s) reported.  Many of the remainder had a clinician (diabetologist or 
general practitioner) as co-author and included an (often short and speculative) 
discussion on how the findings might be applied in clinical practice. Three described 
their score as a ‘clinical prediction rule’.60 66 74  
 
Details of the components of the 94 risk scores included in our final sample and their 
statistical properties – including (where reported) their discrimination, calibration, 
sensitivity, specificity, positive and negative predictive value, and AUROC – are shown 
in Appendix 4 (Table 2).  Many papers offered additional sophisticated statistical 
analysis, though there was no consistency between research teams in the approach or 
statistical tests used.  Heterogeneity of data (especially demographic and ethnic 
diversity of validation cohorts and different score components) in the primary studies 
precluded formal meta-analysis.   
 
All 94 risk scores presented a combination of risk factors as significant in the final 
model, and different models weighted different components differently.  The number of 
components in a single risk score varied from 3 to 14 (n=84, mean 7.8, SD 2.6).  The 
seven scores which we classified as having high potential for use in practice offered 
broadly similar components and had similar discriminatory properties (AUROC 0.74-
0.85).  These seven highlighted scores are show in Table 3.   
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SCORE/STUDY, 
COUNTRY, 
AUTHOR/YEAR 
RISK FACTORS INCLUDED 
IN SCORE 
AUROC CALIBRATION EXTERNAL VALIDATION 
Year, Country AROC CALIBRATION 
ARIC, Germany 
(Atherosclerosis Risk in 
Communities; Schmidt 
2005)
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Age, ethnicity, waist 
circumference, height, systolic 
blood pressure, family history of 
diabetes, fasting plasma glucose 
levels, triglyceride levels, high 
density lipoprotein cholesterol 
levels 
0.80 Not stated 2010,
76
 USA  0.84 HL p<0.001, after 
recalibration p>0.10 
Ausdrisk, Australia 
(Chen 2010)
51
  
Age, sex, ethnicity, parental 
history of diabetes, history of 
high blood glucose, use of 
antihypertensive drugs, smoking, 
physical inactivity, waist 
circumference 
0.78 HL p=0.85 Not externally validated but has been studied as part 
of an intervention to improve outcomes
90
 
Cambridge Risk Score, 
UK (Rahman 2008)
80
 
Age, sex, use of current 
corticosteroids, use of 
antihypertensive drugs, family 
history of diabetes, body mass 
index, smoking 
0.74 with 
threshold 
of 0.38 
Not stated 2010,
81
 UK*  0.72 HL P=0.77 
FINDRISC, Finland 
(Lindstrom 2003)
33
 
Age, body mass index, waist 
circumference, use of 
antihypertensive drugs, history 
of high blood glucose, physical 
inactivity, daily consumption of 
vegetables, fruits, and berries 
0.85 Not stated 2010,
68
 
Holland, 
Denmark, 
Sweden, UK, 
Australia*  
0.76 HL p =0.27 
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Framingham Offspring 
Study, USA (Wilson 
2007)
66
 
Fasting plasma glucose levels, 
body mass index, high density 
lipoprotein cholesterol levels, 
parental history of diabetes, 
triglyceride levels, blood 
pressure 
0.85 Not stated 2010,
76
 USA  0.78 HL p<0.001, after 
recalibration p>0.10 
San Antonio Risk 
Score, clinical model, 
USA, (Stern 2002)
32
 
Age, sex, ethnicity, fasting 
plasma glucose levels, systolic 
blood pressure, high density 
lipoprotein cholesterol levels, 
body mass index, family history 
of diabetes in first degree 
relative 
0.84 HL P>0.2 2010,
76
 USA  0.83 HL p<0.001, after 
recalibration p>0.10 
2010,
70
 Iran *  0.83 HL p≤0.001 after 
recalibration P=0.131 
2010,
81
 UK*  0.78 HL P=0.42 
2010,
84
 Iran*  0.78 HL P=0.264 
QDScore, UK 
(Hippisley-Cox 2009)
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Age, sex, ethnicity, body mass 
index, smoking, family history 
of diabetes, Townsend 
deprivation score, treated 
hypertension, cardiovascular 
disease, current use of 
corticosteroids 
0.83 men, 
0.85 
women 
Brier score 0.078 
men, 0.058 
women  
2011,
72
 UK  0.80 
men, 
0.81 
women 
Brier Score 0.053 men, 
0.041 women 
 
Table 3: Components of seven diabetes risk models or scores with potential for adaptation for use in routine clinical practice 
*Validation used more, less or substituted risk factors from the original risk score or did not state the exact factors it used.  
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These seven validated diabetes risk scores were judged to be the most promising for use in 
clinical or public health practice.  The judgments on which this selection was based were 
pragmatic; other scores not listed in Table 3 could possibly prove more fit for purpose in 
certain situations and settings.  One score that had not yet been externally validated 
according to the pre-set criteria was included in Table 3 as it was already being incentivised 
in a national diabetes prevention policy.
91
   This Australian government scheme is targeted 
at middle aged adults 40-49 years (15-54 years for Aboriginal or Torres Strait Islander 
peoples), and attracts a Medicare rebate.  High risk individuals undergo further assessment 
by their GP which may involve a reduced cost lifestyle intervention.  This risk score was 
also included in the qualitative part of the review for studies using diabetes risk models or 
scores as part of an intervention to improve outcomes (Appendix 4, Table 5).
90
  Subsequent 
correspondence with the author revealed a small validation study on approximately 500 
women who were part of a separate osteoporosis study, that had been reported in a letter to 
the Medical Journal of Australia.
92
  
 
Overall, AUROCs ranged from 0.60 to 0.91.  Certain components used in some scores (e.g. 
biomarkers) are rarely available in some pathology laboratories and potentially too 
expensive for routine use.  Some models which exhibited good calibration and 
discrimination on the internal validation cohort performed much less well when tested on 
an external cohort
79 85
 suggesting that the initial model may have been overfitted by 
inclusion of too many variables that had only minor contributions to the total risk.
93
  
Overfitting arises because any given risk factor in the score does not occur very frequently 
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in the original derivation study.  This manifests itself most noticeably when the score is 
used on a different population, and produces incongruent results.
94
  Whilst genetic risk 
scores were not sought out, those studies which had included genetic markers alongside 
socio-demographic and clinical data all found that the former added little or nothing to the 
overall model.
50 64 78 81
  
 
Reporting of statistical data in some studies was very incomplete.  For example, only 40 of 
the 94 models quantified any form of calibration statistic. There were 43 which presented 
sensitivity and specificity, 27 justified the rationale for cut-off points, 22 presented a 
positive and 19 a negative predictive value, and 26 made some attempt to indicate the 
percentage of the population that would need clinical follow-up or testing if they scored 
‘high risk’.  Some models performed poorly (e.g. there was a substantial gap between 
expected and observed numbers of participants who developed diabetes over the follow-up 
period).  The false positive and false negative rates in many scores raised serious questions 
about their utility in clinical practice (e.g. positive predictive value ranged from 5 to 42%; 
negative predictive value ranged from 88 to 99%).  However, some scores were designed as 
non-invasive preliminary instruments with a recommended second phase involving a blood 
test.
39 58 67 68 70 73 83
  Risk models and scores tended to ‘morph’ when they were externally 
validated because research teams dropped components from the original (for example, if 
data on these were not available), added additional components (for example, to 
compensate for missing categories), or modified what counted in a particular category (for 
example, changing how ethnicity was classified); in some cases these modifications were 
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not clarified.  Since a key dimension of implementation is appropriate adaptation to a new 
context, this probably did not negate the external validation.   
 
The qualitative findings from the risk scores are shown in Appendix 4 (Table 3).  Of the 43 
papers in the full sample, three did not recommend use of the model tested because the 
authors felt it had no advantage over existing approaches.
64 71 75
  Authors of the other 40 
papers considered that at least one of their score(s) should be adopted and used, and made 
various claims to justify this.  The commonest adjective used by authors to describe their 
score was ‘simple’ (26 out of 43); others included ‘low-cost’, ‘easily implemented’, 
‘feasible’ and ‘convenient’.   
 
In total, 16 of the 43 studies which recommended use of a particular risk model or score did 
not designate an intended user for it.  Some authors assigned agency to a risk score (i.e. 
they stated, perhaps inadvertently, that the score itself had the potential to prevent diabetes, 
change behaviour or reduce health inequalities).  Whilst most authors did state an intended 
target group, this was usually given in vague terms (e.g. ‘the general population’ or 
‘individuals who are likely to develop diabetes in the near future’).  Eleven of the 43 papers 
gave a clear statement of what intervention might be offered, and by whom, to people who 
scored above the cut-off for high risk.  The other papers made no comment on this or used 
vague terms such as ‘preventive measures’ without specifying who would deliver these.   
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In all, the authors of the papers in our full sample either explicitly identified or appeared to 
assume ten mechanisms by which (singly or in combination) use of the diabetes risk scores 
might lead to improved patient outcomes: 
 
1. Clinical 
Direct impact - clinicians will pick up high risk patients during consultations and offer 
advice that leads to change in patients’ behaviour and lifestyle. 
Indirect impact - routine use of the score increases clinicians’ awareness of risk for diabetes 
and motivation to manage it. 
2. Self assessment 
Direct impact - people are alerted by assessing their own risk (for example, using an online 
tool), directly leading to change in lifestyle. 
Indirect impact - people, having assessed their own risk, are prompted to consult a clinician 
to seek further tests or advice on prevention. 
3. Technological 
Individual impact - a risk model programmed into the electronic patient record generates a 
point of care prompt in the clinical encounter. 
Population impact - a risk model programmed into the electronic patient record generates 
aggregated data on risk groups, which will inform a public health intervention. 
4. Public health 
Planners and commissioners use patterns of risk to direct resources into preventive 
healthcare for certain subgroups. 
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5. Administrative 
An administrator or healthcare assistant collects data on risk and enters these onto the 
patients’ records, which subsequently triggers the technological, clinical, or public health 
mechanisms. 
6. Research into practice 
Use of the risk score leads to improved understanding of risk for diabetes or its 
management by academics, leading indirectly to changes in clinical practice and hence to 
benefits for patients. 
7. Future research 
Use of the risk score identifies focused subpopulations for further research (with the 
possibility of benefit to patients in later years). 
 
Risk models and scores had been developed in a wide range of different health systems. 
Differences in the components of the scores could be explained partly in terms of their 
intended context of use (which in turn were specific to the setting and health system).   
 
None of the 43 papers that validated one or more risk scores described the actual use of that 
score in an intervention phase.  Furthermore, whilst these papers had been cited by a total 
of 1,883 (range 0-343, median 12) subsequent papers, only nine of those 1,883 papers 
(listed in Appendix 4 (Table5)) described application and use of the risk score as part of an 
impact study aimed at changing patient outcomes.  These covered seven studies, of which 
three had reported definitive results.  All three reported positive changes in individual risk 
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factors, but surprisingly none recalculated participants’ risk scores after the intervention 
period to see if they had changed.  Whilst one report on the ongoing FIN-D2D study 
suggests that incident diabetes has been reduced in ‘real world’ (i.e. non-trial) participants 
who were picked up using a diabetes risk score and offered a package of preventive care,
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this is a preliminary and indirect finding based on drug reimbursement claims, and no 
actual data are given in the paper.  With that exception, no published impact study on a 
diabetes risk score has yet demonstrated a reduction in incident diabetes.  
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Discussion 
 
The lengthy background to this section of the thesis in chapter 4 highlighted the complexity 
of type 2 diabetes risk models and scores.  A brief review of the literature by a public health 
specialist or general practitioner is unlikely to result in quick translation of risk scores into 
everyday practice.   A systematic review was needed to make sense of this field of research.  
Methodology for the review as described in Chapter 4 was complex and evolved iteratively 
to take account of the diversity of diabetes risk scores.   
 
The results of the systematic review have demonstrated that a small number of diabetes risk 
models and scores exist based on data that are readily available and which provide a good 
but not perfect estimate of the chance that a non-diabetic adult will develop diabetes in the 
medium-term future.  A few research teams have undertaken exemplary development and 
validation of a robust model, reported its statistical properties thoroughly, and followed 
through with studies of impact in the real world.   
 
Included studies were not entirely free from bias and confounding.  This is because the 
‘pragmatic’ use of a previously assembled database or cohort to develop or validate a 
diabetes risk score brings an inherent selection bias, as described previously.  For example, 
the British Regional Heart Study cohort was selected to meet the inclusion criteria for age 
and co-morbidity defined by its original research team and oriented to research questions 
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around cardiovascular disease; the population for the QDScore is drawn from general 
practice records and hence excludes those not registered with a GP).   
 
Most papers in the final sample of 43 papers had one or more additional limitations.  They: 
[a] reported risk models or scores that required collection of data not routinely available in 
the relevant health system, [b] omitted key statistical properties such as calibration and 
positive and negative predictive values that would allow a clinician or public health 
commissioner to judge the practical value of the score, or [c] omitted to consider who 
would use the score, on whom and in what circumstances.  It was identified that there was a 
mismatch between the common assumption of authors who develop a risk model (that their 
‘simple’ model can now be taken up and used) and the actual uptake and use of such 
models (which seems to happen very rarely).  However, there has recently been an 
encouraging – if limited – shift in emphasis from the exclusive pursuit of statistical 
elegance (e.g. maximising AUROC) to undertaking applied research on the practicalities 
and outcomes of using diabetes risk scores in real-world prevention programmes.   
 
The strengths of the systematic review are: [a] use of mixed methodology, [b] orientation to 
patient-relevant outcomes, [c] extraction and double-checking of data by five researchers, 
and [d] inclusion of a citation-track to identify recently published studies and studies of 
impact.  Both standard systematic review methods (to undertake a systematic and 
comprehensive search, translate all non-English texts, and extract and analyse quantitative 
data) and realist methods (to consider the relationship between the components of the score, 
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the context in which it was intended to be used and the mechanism by which it might 
improve outcomes for patients) were employed.   
 
The main limitation of the review is that data techniques and presentation in the primary 
studies varied so much that it was problematic to determine reasonable numerators and 
denominators for many of the calculations.  This required pragmatic decisions to be made 
to collate and present data as fairly and robustly as possible while also seeking to make 
sense of the vast array of available scores to the general medical reader.  It is recognised 
that the final judgement on which scores are, in reality, easy to use will lie with the end-
user in any particular setting.  Secondly, authors of some of the primary studies included in 
this review were developing a local tool for local use and made few or no claims that their 
score should be generalised elsewhere.  Yet, the pioneers of early well-known models
32 33
 
have occasionally found their score being applied to other populations (perhaps ethnically 
and demographically different from the original cohorts), their selection of risk factors 
being altered to fit the available categories in other datasets, and their models being re-
calibrated to provide better goodness of fit.  All this revision and recalibration to produce 
‘new’ scores makes the systematic review of such scores at best an inexact science.   
 
After finalising the systematic review, and prior to publication in the BMJ, two separate 
systematic reviews were published by teams in Cambridge
96
 and Oxford.
94
  These reviews 
applied a different but complementary approach.   
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The Cambridge Review was undertaken by long term experts in diabetes risk scores, 
including the original author of the Cambridge Diabetes Risk Score, which is world 
renowned.
31
  Although this score was created from cross-sectional data, it was later used in 
a cohort study by Rahman et al in 2008
80
 and was hence included in the systematic review 
included within this thesis (the London Review).  The Cambridge Review’s aim was 
threefold: [a] to identify scores for diabetes risk prediction, [b] to evaluate performance in a 
new population, of scores derived and validated elsewhere, and [c] analysing 
methodological difficulties.  They also only included cohort studies of adults that excluded 
persons with diabetes at cohort inception.  Like my colleagues and I, they also had to make 
pragmatic decisions in a complex field.  For example, they decided where scores appeared 
in more than one paper, to include the paper that had the most detail on that score’s 
performance, as oppose to the approach in the London Review which resulted in analysis of 
39 external validations of 14 models or scores.  Although they collected similar statistical 
information on each score (including calibration) it was of note that in the main table in the 
published paper they chose only to present discrimination.  Whilst this is understandable as 
it is the statistic that is most often complete, it is only part of the picture of performance as 
described in Chapter 4.  Comparison of discrimination between scores as new risk factors 
are added and subtracted, and different population groups experimented on, has clearly 
been a large part of this research field and the academic competition between different 
teams.  As experienced researchers the Cambridge Review in this sense represents the 
expected review from the leaders of this field.  The results catalogued a list of descriptive 
statistics without meta-analysis.  A qualitative assessment of real world impact was not 
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performed (and not expected given the background of the research team).   The Cambridge 
team’s conclusions included: [a] that risk score performance differed in new populations 
when derived from studies with varying ethnic structures, [b] that there were scores that 
used easily obtainable data, [c] that identifying high risk groups could help with targeted 
prevention efforts, and [d] that scores which included glycaemic indices (or other blood 
tests) performed better.   
 
By contrast, the Oxford Review was carried out by an experienced research team without 
specific expertise in diabetes risk scores.  This same team also externally validated the 
QDScore on a new population
72
, and are developing a track record of validating other risk 
scores derived from the creators of the QDScore.
97-100
  The Oxford Review had a different 
focus to both Cambridge and London approaches, reviewing primarily methods rather than 
performance.  They also reviewed scores for undiagnosed diabetes, hence their review is 
not strictly comparable to the London and Cambridge Reviews.  Appropriately, they 
extracted fields from their dataset including coding and model-building strategies.  And like 
the other two reviews they performed no meta-analysis.  In their findings section, these 
authors focused on the poor and unstandardised methodology of models and scores.   
 
Together the three reviews cover methodological, statistical, and ‘application in the real 
world weaknesses’, and whilst there is some duplication, the different angles of the reviews 
make them complementary to addressing different aspects of risk models and scores.  All 
three reviews highlight the complex and disparate nature of risk models and scores, and 
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pave the way for a standard approach to derivation, validation and application, which is, at 
present, lacking.   
 
The finding that diabetes risk scores appear to be rarely used can be considered in the light 
of the theoretical literature on diffusion of innovation.  As well as being a mathematical 
model, a risk score can be thought of as a complex, technology-based innovation, the 
incorporation of which into business as usual (or not) is influenced by multiple contextual 
factors.  This includes the attributes of the score in the eyes of potential adopters (relative 
advantage, simplicity and ease of use); adopters’ concerns (including implications for 
personal workload and how to manage a positive score); their skills (ability to use and 
interpret the technology); communication and influence (e.g. whether key opinion leaders 
endorse it); system antecedents (including a healthcare organisation’s capacity to embrace 
new technologies, workflows and ways of working); and external influences (including 
policy drivers, incentive structures and competing priorities).
101 102
 
 
Whilst the developers of most diabetes risk scores are in little doubt about their score’s 
positive attributes, this confidence seems not to be shared by practitioners, who may doubt 
the accuracy of the score and/or the efficacy of risk modification strategies.  Measuring 
diabetes risk competes for practitioners’ attention with a host of other tasks, some of which 
bring financial and other rewards.  Furthermore the very low positive predictive values may 
spell trouble for commissioners.  Identifying a person as ‘[possibly] high risk’ will 
inevitably entail a significant cost in clinical review, blood tests and (possibly) intervention 
 78 
 
and follow-up.  Pending the results of ongoing impact studies, this may not be the best use 
of scarce resources.   
 
Whilst most authors of papers describing diabetes risk scores have hypothesised (or appear 
to have assumed) a clinical mechanism of action (i.e. that the score would be used by the 
individual’s clinician to target individual assessment and advice), the limited data available 
on impact studies suggest that a particularly promising area for further research is 
interventions which prompt self-assessment (i.e. lay people measuring their own diabetes 
risk).   Risk scores which rely entirely on such questions may be hosted on the Internet (see 
for example http://www.diabetes.org.uk/riskscore).  Some researchers have used self-
completion postal questionnaires as the first part of a step-wise detection programme.
103
  To 
the extent that these instruments are valid, they can identify two types of individual: [a] 
those who already have diabetes whether they know it or not (hence, the questionnaire may 
serve as a self-administered screening tool for undiagnosed diabetes) and [b] those at high 
risk of developing diabetes (hence, it may also serve as a prediction tool for future 
diabetes).  Hence, diabetes prevalence rates derived from self-assessment studies cannot be 
compared directly with the incident diabetes rate in a prospective longitudinal sample from 
which those testing positive at baseline have been excluded.   
 
The findings did not support the recommendation of a single, preferred diabetes risk score.  
There is no universal ‘ideal’ risk score, since the utility of any score depends not merely on 
its statistical properties but also on its context of use, which will also determine which 
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types of data are available to be included.
41 104
  Even when a risk model has excellent 
discrimination (and especially when it does not) the trade-off between sensitivity and 
specificity plays out differently depending on context.   
 
Listed below are some suggested questions a public health specialist, general practitioner or 
commissioner could ask when faced with the dilemma of which risk score to use:   
 
What is the intended use case for the score? 
If intended for use: 
 In clinical consultations - the score should be based on data on the medical record 
 For self assessment by lay people - the score should be based on things a layperson 
 would know or be able to measure. 
 In prevention planning - the score should be based on public health data. 
 
What is the target population?  
If intended for use in high ethnic and social diversity, a score that includes these variables 
may be more discriminatory. 
 
What is expected of the user of the score? 
If for opportunistic use in clinical encounters, the score must align with the structure and 
timeframe of such encounters and competencies of the clinician, and (ideally) be linked to 
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an appropriate point of care prompt.  Work expected from the intended user of the score 
may need to be incentivised or remunerated, or both. 
 
What is expected of the participants?  
If to be completed by lay people, the score must reflect the functional health literacy of the 
target population. 
 
What are the consequences of false positive and false negative classifications? 
In self completion scores, low sensitivity may falsely reassure large numbers of people at 
risk and deter them from seeking further advice. 
 
What is the completeness and accuracy of the data from which the score will be 
derived? 
A score based on automated analysis of electronic patient records may include multiple 
components but must be composed entirely of data that are routinely and reliably entered 
on the record in coded form, and readily searchable (thus, such scores are only likely to be 
useful in areas where data quality in general practice records is high). 
 
What resource implications are there?  
If the budget for implementing the score and analysing data is fixed, the cost of use must 
fall within this budget. 
 81 
 
Given the above, what would be the ideal statistical and other properties of the score 
in this context of use? 
What trade-offs should be made (sensitivity v specificity, brevity v comprehensiveness, one 
stage v two stage process)?  
 
Millions of participants across the world have already participated in epidemiological 
studies aimed at developing a diabetes risk score.  There is now a menu of possible scores 
available to those who seek to use them and/or validate them in new populations, none of 
which is perfect but all of which have strengths.   
 
My initial impression of diabetes risk scores being too numerous and too inaccessible for 
GPs or public health specialists to readily decide which one to use in practice, was to an 
extent allayed by the findings from the systematic review.  It appeared that in a vast and 
methodologically complex area, suitable risk scores which had potential to be readily 
adapted for any given clinical or public health uses were available.  I was satisfied that 
performance had been documented comprehensively, and most importantly impact 
assessed, revealing that this was mostly absent.   
 
The next challenge was to take a readily accessible and usable score and study the 
feasibility of using it in real life practice.  With this conclusion from the systematic review, 
I moved to the next stage of this research and chose one of the scores to use on the local 
population in East London, presented in Section 3.   
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SECTION 3: Cross-Sectional Analysis of Electronic General Practice Records 
Chapter 5: Background, Aims, Methods 
 
In this section, in the context of the epidemic of type 2 diabetes described in Section 1, and 
the availability of some suitable risk scores for use in clinical and public health practice 
from the review in Section 2, I sought to translate and apply this research in a real world 
setting.  Having lived and worked in East London for some years I was already aware of the 
great needs for prevention of diabetes and its common risk factors, such as obesity.  In this 
section I will describe the setting and population of East London, how I selected one of the 
risk scores to use on local electronic general practice records, outline the aims and methods 
of an empirical cross-sectional study, and present selected results with accompanying 
discussion.   This was published as a special report on diabetes risk for local NHS partners 
and is available on the Queen Mary University London website.  The academic paper has 
been submitted to the British Journal of General Practice and is currently being peer 
reviewed.  This can be found in Appendix 5.   
 
Background 
 
Inner North East London comprises the boroughs of Tower Hamlets (population 
241,747)
26
, Newham (population  265,688)
23
 and City (population 9,502) & Hackney 
(population 229,036).
24
  These make up three PCTs as City & Hackney are grouped 
together.  The estimated population size overall using Greater London Authority estimates 
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from the most recent Joint Strategic Needs Assessments and the Tower Hamlets Population 
Change and Growth Model is 745,973.   
 
East London is ethnically diverse and of low socioeconomic status compared to England as 
a whole.  Joint Strategic Needs Assessments reveal non-white ethnic groups make up 
approximately 50% of the population in Tower Hamlets, 40% in Hackney, 20% in the City 
and 70% in Newham.  Certain ethnic groups suffer low-literacy and obesity.  The 
combination of ethnicity (generational and genetic risk) and cultural/linguistic barriers 
combined with poverty, increase the risk of diabetes significantly.  The three areas ranked 
3
rd
 (City&Hackney), 4
th
 (Tower Hamlets) and 7
th
 (Newham) for highest Index of Multiple 
Deprivation (IMD) in England in 2007.
105
  Tower Hamlets moved down to 8
th
 place in the 
2010 figures as shown in Table 4.
106
   
 
Primary Care 
Trust  
Average IMD 
Score 2010 (higher 
is more deprived) 
National rank of average score 
(higher ranking is more deprived – 
out of a total of 152 PCTs) 
Newham  41.84 3
rd
  
City and Hackney 41.28 4
th
  
Tower Hamlets  39.59 8
th
  
For comparison average Index of Multiple Deprivation score in 2010 in England was 21.67.   
Table 4: East London Index of Multiple Deprivation 2010 
 
The registered general practice population is significantly higher than the geographical 
population due to people remaining on lists after leaving the area and people who are 
registered but do not live in the boroughs.  When the cross-sectional study took place the 
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general practice registered population was 881,896 (135,923 higher).  Over the last six 
years the registered population has increased by 143,000 (increases of 25% in Tower 
Hamlets, 19% in Newham and 13% in Hackney).
22
  The number of practices has remained 
relatively stable at approximately 145.   
 
The majority of these 145 practices are on the same patient record system - the Egton 
Medical Information System (EMIS).  EMIS is an electronic GP database used by 55% of 
English practices.  Uniquely in East London the electronic records are accessible at Queen 
Mary University London (QMUL), pending appropriate permissions, via the Clinical 
Effectiveness Group (CEG), an academic unit within the medical school, co-directed by Dr. 
John Robson (JR) a local GP, and staffed by general practitioner academics, statisticians 
and facilitators.  CEG’s aim is to use routinely collected data from local general practices to 
inform needs assessment and public health planning while also contributing to the academic 
knowledge base in primary care and public health.  It produces routine reports for local 
general practices and PCTs on their clinical performance.  An established standing 
agreement enables the university-based CEG to access and audit non-identifiable service 
and clinical data.  This central access to records made this cross-sectional analysis possible.   
 
EMIS has three principal forms.  EMIS LV is the most common and can be likened to MS 
DOS.  It is used by 90% of practices.  EMIS PCS is a newer version of EMIS used by 10% 
of practices.  It has an interface akin to using Microsoft Windows but lacks some of the 
functionality of the older EMIS LV program (i.e. search and report functionality is not as 
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sophisticated).  EMIS web (the web based version of EMIS) is being used by a growing 
number of practices throughout East London (currently primarily in Newham) and is the 
gold standard.  It is anticipated that by the end of next year, all EMIS practices will be 
using EMIS web as their primary system.   
 
Previously, before 2010, in order to run and export searches a program called MIQUEST 
(Morbidity Information Query and Export Syntax) was used to generate search strings and 
then every practice was visited in person to run that search on their individual practice.  
Results were then collated.  This was time intensive and costly.  With email this process 
was slightly speeded up.   
 
Currently, however, for all practices using EMIS LV or EMIS PCS, all of the information 
is transmitted electronically via nhs.net to a server in Leeds, and reflected back to practices 
and authorised organisations in a read-only format in EMIS web.  The full live version of 
EMIS web allows practices to edit data in real time within a secure Internet cloud, as well 
as share with authorised organisations (including CEG).   
 
The data are accessible to authorised organisations.  In the local area there are three main 
organisations with the necessary permissions to access the data (though individual practises 
may extend permissions to a wider group of organisations).  Firstly, data are accessible to 
the individual practices who can see their data only in EMIS web form, meaning they have 
two active forms of EMIS available to them (EMIS LV/PCS and EMIS Web).  Secondly, 
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the immunisation reporting data is accessed directly by the PCTs.  Thirdly, the dataset is 
accessed by CEG who can create aggregated reports from the data, or view anonymised 
individual patient lines of categorical data.   
 
CEG has an annually renewable agreement with all of the EMIS practices across East 
London to access patient data and use it for clinical audit and reporting purposes. Practices 
can freely view all of the searches and reports created by CEG and opt out of this 
agreement at any time. Currently, only one practice does not consent to share information.   
 
Use of potentially identifiable clinical data requires discussion with the National 
Information Governance Board (NIGB) as people have not consented to their identifiable 
individual data being used.  Typically identifiable data would include such fields as name, 
address, full postcode, date of birth (rather than age in years) and NHS number.  In some 
circumstances it might also include reported cells with small numbers. CEG does not access 
any of this identifiable information without NIBG agreement.   
 
CEG’s anonymised reporting data takes two forms, aggregate reports e.g. 25% of patients 
have risk factors for Cardiovascular Disease (CVD), and list reports, with pieces of 
information for each individual patient e.g. age, sex, ethnicity, family history of diabetes 
etc.   
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Selection of a diabetes risk score for East London 
 
Drawing on the criteria developed during the systematic review and using the shortlist of 
seven practical risk scores in Table 3, a risk score for use on the electronic records via CEG 
in East London was sought.   
 
Using these criteria the QDScore was selected for the following reasons: [a] the intended 
use case was likely to be primarily in clinical consultations (although public health uses are 
possible through aggregation of data at CEG) and QDScore uses electronic data from GP 
records which are highly complete in East London, [b] the target population is ethnically 
and socially diverse and QDScore incorporates these variables, and [c] the expected user 
(the GP) in clinical practice could potentially incorporate the score automatically within the 
incentivised NHS Health Checks
43
 (QRisk
42
 is already used in this context for 
cardiovascular risk and therefore costs are likely to be low to add in QDScore).      
 
The QDScore
54
 gives a ten year estimate of risk of developing type 2 diabetes.  The risk 
factors used are: age, gender, ethnicity, Townsend score of deprivation (based on Census 
derived unemployment, car ownership, owner occupation and overcrowding), family 
history of diabetes, history of cardiovascular disease, smoking status, treated hypertension, 
current corticosteroid usage and BMI (weight and height).  It incorporates ethnicity and 
socio-economic deprivation together and has been created in a prospective study population 
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(using the QResearch database).  The QResearch database is composed of a generalisable 
sample from England and Wales of 11 million electronic records from 551 general 
practices derived from EMIS.
54
   
 
QDScore has only been derived and externally validated on populations aged 25-79 years 
free from diabetes at baseline.
54 72
  For derivation and internal validation, two cohorts were 
created randomly.  To derive the score 2,540,753 individuals aged 25-79 years were used.  
The internal validation cohort had 1,232,832 individuals.    In the derivation cohort 78,081 
people developed diabetes compared to 37,535 in the internal validation cohort.  The study 
period ran for 15 years from 1993 to 2008.  Ethnicity was a major risk factor as was 
deprivation.  The AUROC was 83.4% for women and 85.3% for men.  Calibration was also 
good as observed and predicted rates of diabetes were closely aligned.  It was externally 
validated on the THIN database by independent researchers.
72
  
 
The mathematical equation for QDScore is highly complex and can be found online.
107
  
QDScore is most accurate when electronic general practice records are complete.  
However, if variables are missing QDScore approximates a score using assumptions.  Table 
5 shows how the score handles missing values.   
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Missing value QDScore response 
Townsend score Assumes value is 0 (national average) 
BMI Substituted value used based on prediction algorithm using age, sex, 
ethnicity, smoking status, treated hypertension and cardiovascular 
disease  
 
If BMI is out of range the processor substitutes a BMI of either 15 or 54 
Ethnicity Defaults to White British 
Smoking Assumes not a smoker 
Table 5: QDScore and missing values 
 90 
 
Aim of the cross-sectional study 
 
To use a risk prediction model on the electronic records of three inner city boroughs to 
describe risk of diabetes to guide possible interventions for targeting groups at high risk.   
 
The research question was:  
How feasible is it to aggregate, describe, and stratify diabetes risk in a way that 
meaningfully informs locality-based needs assessment and service planning? 
 
Objectives 
1. To use the EMIS web database in Inner North East London to calculate 10-year 
diabetes risk using the QDScore on the GP-registered population aged 25-79 years.   
2. To describe risk by age, gender, ethnicity, social deprivation and other co-
morbidities. 
3. To categorise risk and describe in detail the characteristics of the high-risk 
population.   
 
The final aim and objective as presented above was initially much broader and was 
modified iteratively as the study progressed.  An initial decision was also made to 
geospatially map some of the findings and this is presented separately in Section 4.  
However, in the course of the overall research both the cross-sectional analysis and 
geospatial mapping (and the latter stages of the systematic review) were conducted with 
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some overlap, although they have been separated in this thesis - mainly for ease of reading, 
and also because each has yielded separate research findings and an academic publication.   
 
Methods 
 
A cross-sectional analysis was undertaken on 519,288 electronic general practice records of 
all non-diabetic adults aged 25-79 years from EMIS Web across 135 out of 145 general 
practices in the boroughs of Tower Hamlets, Newham and City & Hackney.   
 
Anonymised data were extracted from electronic health records in general practices using 
EMIS Web via N3 networks which are securely held by CEG at QMUL.  The ten clinical 
variables needed to calculate the QDScore
54
 were extracted from the records: age, gender, 
ethnicity, Townsend score of deprivation, family history of diabetes, personal history of 
cardiovascular disease, smoking status, treated hypertension, current corticosteroid usage 
and BMI.  Additional clinical variables were also extracted for sub-group analysis 
including: QRisk II (referred to as QRisk throughout, and only for people over 30 years), 
diagnosed hypertension without treatment, estimated glomerular filtration rate (eGFR), and 
gestational diabetes (females only).   
 
The QDScore was supplied as an electronic patch by the original authors (Hippisley-Cox, 
personal communication to RM & JR) and used to calculate risk of type 2 diabetes.
54
  Basic 
descriptive statistics were compiled using Stata version 10.
108
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QDscore results were grouped into quintiles of type 2 diabetes risk for analysis.  In some 
cases the bottom quintile, relating to a risk of less than 20%, was split in half for further 
exploration during the sub-group analysis.  Certain other variables had to be categorised, 
and a quintiles approach was used for much of the analysis, as shown in Table 6.  Risk of 
type 2 diabetes was further categorised as low (0-9.99% risk at ten years), medium (10-
19.99%) and high (≥20%).   
 
Variable Groups 
Diabetes Risk 0-19.99, 20-39.99, 40-59.99, 60-79.99, 80-100 
Townsend Score -6 to 3, 4, 5, 6, 7-10 
BMI 10-19.99, 20-24.99, 25-29.99, 30-34.99, 35-49.99, 50-70 
QRISK 0-9, 10-19, 20-29, 30-39, 40+ 
Table 6: Grouping techniques for variables 
 
Sub-group analyses using descriptive statistics, with variables used to calculate the 
QDScore (age, sex, ethnicity, deprivation, treated hypertension, personal history of 
cardiovascular disease, and body mass index), and the additional clinical variables not 
included in the score, were undertaken.  Diagnosed hypertension with treatment was used 
for the QDScore patch.  However, diagnosed hypertension overall with or without 
treatment was used for sub-group analysis.  These variables were selected after discussion 
amongst the research team, local general practitioners and public health specialists as to 
which would be most useful to inform commissioning of public health interventions.   
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Sub-groups with higher risk were described but not unexpected as certain predictor 
variables within the QDScore patch lead to a higher score (e.g. certain ethnicities).  
Therefore statistical colinearity between the outcome (% risk) and the predictor variables 
rendered tests of significance misleading.   
 
For the purposes of QDScore calculation, ethnicity codes were grouped into 17 categories 
based on the 2001 census.  General practices in the three boroughs have access to 155 
ethnic group codes.  These were converted to 17 (using a standard process described with 
the QDScore processor manual supplied by the original authors) in order to use the 
QDScore electronic patch.  After combining the calculated QDScore with the variables for 
sub-group analysis, ethnic group was reduced from the 17 categories used in the score 
calculation to five for ease of analysis.  Ethnic categories were reduced from 17 to five as 
follows:  White (British, Irish, other White), Black (White+Black African, White+Black 
Caribbean, African, Caribbean, other Black), South Asian (Bangladeshi, Pakistani, Indian, 
other Asian or White+Asian), Other (Chinese, other ethnic groups, other mixed groups), 
and Not stated or Missing (not recorded).  The final category comprised: truly not stated 
(missing), not disclosed, or was coded at too high a level to be useful (effectively missing).  
Individuals who reported being of mixed Black or mixed South Asian were grouped with 
their parent ethnic minority group for reasons of biological plausibility.   
 
Results were further broken down in each of the three individual boroughs so as to supply 
each of the relevant NHS PCTs detailed estimates of those at risk.  The overall results for 
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all three boroughs are presented in this thesis, the detailed borough by borough results and 
analysis can be found in the online report.
109 
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Chapter 6: Results and Discussion 
 
Results 
 
Clinical variables for risk calculation were extracted from 135 out of 145 practices.  Of the 
ten practices not included in the study, one did not share data, four used non-EMIS based 
systems, and five had technical problems which prevented access to data.  A small number 
of individual records were classified as confidential and could not be accessed.  Table 7 
shows the flow of data through the study.   
 
 Tower 
Hamlets 
City & 
Hackney 
Newham Total 
Total number of practices 36 45 64 145 
Number of practices with data 
available 
35 40 60 135 
Registered population 268,130 266,577 347,189 881,896 
Aged 25-79 years 174,596 177,468 216,779 568,843 
Free from Diabetes 163,275 167,685 199,488 530,448 
Data available for analysis 163,088 166,762 189,438 519,288 
Table 7: Flow of data through cross-sectional study 
 
Completeness of variables that should have been routinely collected on the general practice 
electronic records (n=519,288) were as follows: age (100%), gender (100%), ethnicity 
(91.6%), Townsend deprivation score (99.8%), BMI (76.5%), and smoking status (96.4%).  
Other variables were only recorded if positive. [Table 8] Gestational diabetes was positive 
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for 1.02% of females only (n=241,072).  QRisk was calculated for 53.8% of individuals 
over 30 (n=410,874).   
 
Variable Positive (% & number) 
Family history of diabetes 22.9  (n=119,063) 
Personal history of cardiovascular disease 1.9  (n=9,805) 
Diagnosed hypertension with or without treatment 9.3  (n=48,169) 
Treated hypertension 7.2  (n=37,394) 
Current corticosteroid usage 1.01  (n=5,240) 
Estimated glomerular filtration rate <60 1.35  (n=7,026) 
Gestational diabetes (women only) 1.02  (n=2,466) 
Table 8: Completeness of variable recording in cross-sectional study 
 
The distribution of QDScore was plotted and was determined to be heavily skewed to the 
right (as shown in Figure 4).   
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Figure 4: Distribution of QDScore 
 
Overall, 1 in 10 people (n=51,061) in this inner-city population were at high risk (≥20%) of 
developing type 2 diabetes within ten years.   The risk of developing type 2 diabetes rose 
with age from 2.1% of 25-39 year olds (n=6,225) at high risk compared to 20.1% of 40-79 
year olds (n=44,842).  Table 9 shows the proportion of individuals at low, medium and 
high risk of developing type 2 diabetes over the next ten years.   [Table 9, Figure 5] 
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 10 year risk 
of developing 
type 2 
diabetes (%) 
Number of 
people in 
category 
% of 
sample 
Sex  
(% 
male) 
Median 
score 
Median  
age 
White  
% 
(n=214,5
42) 
South 
Asian % 
(n= 
135,000) 
Black 
%  
(n= 
82,036) 
0-9.9 (low) 410,801 79.1 53.0 1.8  34 83.2 69.4 72.4 
10-19.9 
(medium) 
57,426 11.1 55.4 13.8 49 9.4 14.2 15.3 
20-100 (high) 51,061 9.8 56.4 30.9 54 7.5 16.4 12.3 
Total 519,288 100 53.6 2.8 37 100 100 100 
Table 9: Proportion of individuals at low, medium and high risk of developing type 2 
diabetes over the next 10 years 
 
 
Figure 5: Overall number of people at high risk 
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The overall median QDScore varied between different ethnic groups: White 1.9%, South 
Asian 4.4% and Black 4.3%.  More than twice as many South Asians (16.4%) were at high 
risk compared to the White (7.5%) population.  [Figure 6]   
 
 
Figure 6: Percentage of each ethnic group in the high risk category overall 
 
The higher the Townsend Score the more deprived the population; 15,262 people were at 
high risk of type 2 diabetes and in the highest band of Townsend Score.  Those in the 
lowest band of Townsend Score (least deprived), had the lowest number of people at high 
risk (7.7%) compared to the highest band of Townsend Score (12.1%).  South Asian 
ethnicity remained a strong risk factor even in non-deprived sub-populations.  The most 
affluent South Asians (Townsend score -6 to 3) had a higher proportion at high risk than 
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the most deprived at high risk from all ethnic groups, showing the impact of ethnicity on 
risk.   [Figure 7] 
 
 
Figure 7: Percentage of adults at high risk of developing type 2 diabetes in each 
Townsend Score band 
 
Cardiovascular risk as estimated by QRisk was closely associated with high risk of type 2 
diabetes.  For QRisk 0-9, 9.7% (15,516) were at high risk for type 2 diabetes, compared to 
31.1% (12,487) for QRisk 10-19, and 47.7% (9,839) for QRisk ≥20.  [Figure 8] 
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Figure 8: Percentage of adults over 30 at high risk of developing type 2 diabetes in 
each QRisk band 
 
Similarly as shown in Table 10 vascular co-morbidity, eGFR (<60mmls/min/1.73
2
, chronic 
kidney disease stage 3 or greater), gestational diabetes and increasing BMI all increased the 
chance of being at high risk of developing type 2 diabetes.   
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 Number of people 
at high risk 
Number of people 
in category 
Percentage 
at high risk 
CVD (IHD/stroke/TIA) 5,637 9,864* 57.1 
Hypertension 
(diagnosed+/-treatment) 
23,102 48,169** 48.0 
eGFR<60 2,905 7,026 41.3 
Gestational diabetes 446 2,466 18.1 
BMI>30 32,564 76,162 42.8 
QRisk≥20 9,839 20,629 47.7 
Table 10: Percentage of people at high risk in various co-morbidity groups 
*9805 of 9864 had the diagnosis included in the QDScore calculator as nine codes were added later for sub-
group analysis which should have been included in the original score calculation.   
**37, 394 had diagnosed and treated hypertension and this diagnosis was included in the QDscore 
calculation.   
 
In Newham 1 in 8 people (22,513) were at high risk of type 2 diabetes overall (≥20%), 
compared to 1 in 11 people (15,304) in Tower Hamlets and 1 in 13 people (13,244) in City 
and Hackney.  Other small differences were present between each of the boroughs, but 
these are not described in detail in this thesis.   
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Discussion 
 
The QDScore was successfully used on half a million electronic primary care records to 
describe the socially patterned risk of developing type 2 diabetes for an entire inner city 
population.  Risk of adults developing type 2 diabetes was universally high: 1 in 10 people 
(51, 061) were at high risk (≥20%) of developing type 2 diabetes within ten years.  In 
Newham 1 in 8 people (22, 513) were at high risk, compared to 1 in 11 people (15, 304) in 
Tower Hamlets and 1 in 13 people (13, 244) in City and Hackney.   
 
Increasing age and male sex conferred additional risk.  The median age of people at low 
risk (<10%) was 34 years compared to 49 years for those at medium risk (10-20%) and 54 
years for those at high risk (≥20%).  Of 25-39 year olds 2.1% were at high risk compared to 
20.1% of 40-79 year olds.   
 
It is well established that social and ethnic diversity of populations heavily influence 
chronic disease risk.  In the cross-sectional study ethnicity and risk of diabetes were closely 
associated.  More than twice as many South Asians (16.4%) were at high risk compared to 
the White (7.5%) population.  However, high risk was not confined to South Asians.  In 
Newham 10.5% of the White population was at high risk (≥20%) compared to 6.5% in 
Tower Hamlets and 6.5% in City & Hackney.   
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Socio-economic deprivation was associated with increased risk and ethnicity increased this 
association.  Those in the lowest band of Townsend Score have the lowest proportion of 
people (7.7%) who are at high risk (≥20%) compared to the highest band of Townsend 
Score (12.1%).  Within the South Asian population at high risk (22,126) the proportion of 
people at high risk increased and was higher than the overall population in every Townsend 
Score band.   
 
Obesity and cardiovascular co-morbidity substantially increased risk of developing type 2 
diabetes.  For example, 76,162 people in the cohort had a BMI greater than 30, and 42.8% 
of these were high risk for developing type 2 diabetes.  There were 57.2% of people with 
cardiovascular disease, 48.0% with hypertension, 41.3% with chronic kidney disease, and 
18.1% with gestational diabetes who were at high risk for developing type 2 diabetes, 
compared to 9.8% of the cohort overall.   
 
The overlap with QRisk was extensive.  Of those with a QRisk score ≥20 (meaning, ≥20% 
risk of developing cardiovascular disease in 10 years), 48% were also at high risk for 
developing type 2 diabetes.  This underlines the need to combine preventive interventions 
for these common conditions with overlapping risk factors.   
 
The extent of these findings locally was quantified and described.  Although results are not 
surprising, especially as QDScore assigns higher values to known risk factors, detailed 
population sub-group analysis have high potential to inform targeted interventions.   
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The dataset had high completeness due to previous investment and long standing 
relationships between the university, general practices and the primary care trusts.  This 
demonstrates the type of population statistics that can be generated using a risk prediction 
model on electronic records, and the rich level of detail which sub-group analysis can 
generate.  For example, knowing the percentage of an ethnic group at high risk has the 
potential to inform targeted preventive measures through social marketing.   
 
The QDScore has only been validated to estimate risk of diabetes for individuals aged 25-
79 years.  A large proportion of those registered with a GP (n=313,053; 35.5%) was outside 
this age range, reflecting the young population in East London.  Type 2 diabetes is 
increasingly common in younger age groups making this a weakness of the cross-sectional 
study.   
 
Colinearity between outcome and predictor variables prevented tests of statistical 
significance, but as the principle purpose of the descriptive statistics is for service planning, 
and trends were very clear (e.g. association with ethnicity), this is unlikely to impact on the 
routine use of such data.   
 
Whilst many studies exist describing diabetes risk models and scores
94 96 110
, relatively few 
validated scores have described ‘real world’ applications.  The Finnish Type 2 Diabetes 
Risk Score (FINDRISC) was used in a survey of 400 adults aged 20 to 73 years in Libya; 
approximately 12% were at high or very high risk of developing diabetes over ten years.
111
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Both FINDRISC and the Indian Diabetes Risk Score were used on 198 migrants in Norway 
identified through mosques, Norwegian classes, and directly in shops and on the street; 
with FINDRISC 29% were at great/extreme risk (the two highest categories) over ten 
years.
112
  More recently QRISK 2, Framingham and Joint British Societies’ 2 
(cardiovascular risk scoring systems) were offered to 434 South Asians attending Hindu 
temples; using QRISK 2, 15% had a risk greater than 20% of developing cardiovascular 
disease over ten years.
113
  However, all these studies were small and exploratory, and were 
focused mainly on identifying individuals rather than managing risk in entire populations – 
like that presented from this cross-sectional study.   
 
Yet, despite it being feasible to extract a vast quantity of anonymised data to determine 
population estimates of risk, and perform detailed subgroup analysis, making the targeting 
of high risk groups possible, I was concerned about the accessibility of this health 
information to local commissioners.  There were several reasons for these concerns.  First, 
although a summary of the main findings are presented in this thesis, in the report to the 
local NHS partners
109
 pages of detailed figures, tables, and bullet pointed health 
information findings were presented borough by borough.  Having worked in both the 
Department of Health and in a PCT, I was used to observing officials, managers and 
doctors spending only moments glancing over such data, usually in a time-limited allocated 
slot in the midst of vast swathes of other business e.g. as a 15 minute agenda item during a 
two hour monthly vascular care quality group meeting.   Despite their best intentions, it 
appears that many professionals in these situations only engage with the material when they 
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are actually at the meeting, as oppose to studying papers in advance and perhaps making 
better use of the meeting time to critically appraise findings and decide on change in policy.  
For this reason, presenting data in as compelling a way as possible is essential.   
 
Second, the NHS is undergoing radical restructuring, including the transfer of 
commissioning of clinical and public health services to clinical commissioning groups 
(comprising general practitioners, secondary care clinicians, nurses and lay members).
114
  
Part of the public health function will shortly be transferred to local authorities, who are 
traditionally responsible for urban planning and environmental health.  Commissioning and 
local authority bodies will therefore need health information in an easily accessible format 
in order to plan, procure, monitor, evaluate and coordinate clinical and public health 
interventions and neighbourhood initiatives.  My opinion is that tables of data and figures 
alone will not enable these new decision makers to commission effectively.   
 
Third, in the UK, information for health planning and management is ubiquitous.
115
  This 
has been handled traditionally by public health specialists and ancillary staff.  Members of 
the new clinical commissioning groups will need to possess skills in handling health 
information in order to commission services.
116
  Yet, some evidence suggests, at least for 
general practitioners, that both skills in handling and using health information for 
commissioning may be limited.
117
  This could be linked to: [a] lack of training in handling 
and processing population level data, [b] lack of skills in prioritising health information 
based on health needs as oppose to exclusively service demands or cost savings, and [c] 
 108 
 
lack of experience in using health information selectively to plan and manage services and 
public health interventions.  Key to addressing this, in addition to training, is the 
presentation of health information in easily accessible formats, which facilitates clinical 
commissioning groups to develop expertise in using health information for health planning 
and management.   
 
Whilst these concerns may have some merit, there is no ‘one option fits all’ approach to 
health information presentation.  And, although not explored in detail in this thesis, the 
style of the presenter is likely as important as the materials to hand.  Nevertheless, I was 
interested in further exploring geospatial mapping of selected results from the cross-
sectional study, first to explore whether it was possible (as it would potentially entail data 
extraction of half a million postcodes), and second to begin to assess whether this could aid 
operationalising the recently-published NICE guidance on diabetes prevention, which 
recommends the use of: ‘local and national tools … to identify local communities at high 
risk of developing diabetes to assess their specific needs.’13  
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SECTION 4: Geospatial Mapping 
Chapter 7: Background, Aims, Methods 
 
In this section I describe a geospatial study using some of the data from the cross-sectional 
review described in Section 3, and new data containing a geospatial locator for each 
electronic patient record.  This was published in BMJ Open in February 2012.
118
  
[Appendix 6] The extraction of postcodes for geospatial mapping raised a number of 
information governance issues and these were separately explored in a specific information 
governance paper currently submitted to BMC Public Health.  [Appendix 7]  Overall the 
study attracted significant media interest including from the British Broadcasting 
Corporation (BBC) and the Daily Mail.  In Chapter 7 I outline background, aims and 
methods, and in Chapter 8 I present the geospatial maps with accompanying discussion.  
The discussion includes two sub-sections considering information governance issues, and 
the media reporting of the findings.   
 
Background 
 
Historically, mapping has often been used in a public health context.  Early pioneers of 
geospatial mapping of health information included Dr. Alfred Haviland who published in 
1892 his: 'Geographical distribution of diseases in Great Britain,' and most famously the 
mapping by Dr. John Snow of cholera cases surrounding a water pump in Broad Street, 
London, in the mid 1800s.
119 120
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Using health information in the format of geospatial maps enables exploration of spatial 
patterns and geographical associations with wider social determinants of health.
121 122
  For 
example, the International Geographical Union presented a report in Washington, USA in 
1952 from its Commission on: ‘The study of geographical factors concerned with cause and 
effect in health and disease.’123  
 
Presenting health information as maps has various uses, including: [a] idea generation and 
theory formation at project initiation, [b] during scrutiny of research results, and [c] to 
assist with visual presentation of findings to relevant stakeholders.
122
   
 
Geovisualisation – the use of computer-aided graphical methods (Geographic Information 
Systems - GIS) to visualise geospatial information
124
 – is a technique which has begun to 
be used to help guide health service planning, public health interventions and inform the 
public about disease ‘hot spots’.125  A well-known use of this technique are the maps of 
obesity produced by the Center for Disease Control in the USA, which have shown higher 
prevalence in the southern states and a shift in prevalence from low (shown in blue) 
through high (shown in red) over the past 40 years.
126
  
 
Geospatial mapping of self-reported questionnaire data has shown the USA to have a 
‘diabetes belt’ (i.e. a band of states with high prevalence of this condition) in the south-east 
of the country linked to distribution of the known risk factors of obesity, inactivity, and 
African-American ethnicity.
127
  Small-area geographical variation in diabetes prevalence 
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has also been mapped in a single city in Canada using research survey data, and links 
demonstrated with the geographical distribution of social and environmental determinants 
including family income, education, aboriginal status and neighbourhood crime.
128
  In the 
UK, small-area mapping of coronary heart disease morbidity and mortality using multiple 
data sources (e.g. hospital admission statistics and mortality statistics) has been linked to 
social and environmental risk factors (e.g. income and ethnicity) and geographical ‘hot 
spots’ of coronary heart disease demonstrated in localities where these risk factors are 
clustered.
129
  Data from a UK population-based register of arthritis has been used to 
identify geographical clusters of polyarthritis.
130
  
 
 
A key aspect of rigour in geovisualisation of disease or risk of disease is the completeness, 
accuracy, timeliness, accessibility and granularity of the primary data from which the maps 
are constructed, and in particular the extent to which the data are capable of illuminating 
the fine-grained geographical variability needed to inform locality-based health or 
environmental interventions.   
 
Unlike USA and Canada, the UK has the advantage of near-universal registration with 
general practitioners, whose records are at an advanced state of computerisation.
131  
Quality 
of electronically held data is high in most practices, partly due to
 
the national financial 
incentive scheme for general practice, the Quality and Outcomes Framework, a component 
of which is chronic disease management.
132
  Aggregated data from Quality and Outcomes 
Framework returns has been used to model estimates of disease prevalence by locality.
133
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Overall using geospatial maps for chronic disease risk (such as type 2 diabetes) at small 
area level in local districts is at an embryological stage.  Demand is likely to increase as 
more lay practitioners without epidemiological training adopt health planning roles.   This 
is even more likely given the recent advances in general practice computer systems 
including the remote server ‘cloud’ storage of records, with staff gaining access via the 
World Wide Web rather than records held on practice based servers.  This allows 
authorised staff to undertake complex data searches across large numbers of practices, 
allowing the possible use of local general practice records to be used as the data source for 
sophisticated mapping of disease or risk factors by small geographical area.  However, 
accessing and using personal medical data for this purpose raises significant practical, 
technical, ethical and information governance challenges.   
 
Small area geospatial mapping of disease risk factors using electronic primary care records 
as the data source and oriented primarily to an audience of local health planners is 
important when considering dense urban areas where a street may separate relatively poor 
and affluent neighbourhoods.  Models estimating disease prevalence often show greatest 
discrepancy between observed and expected prevalence in areas of social complexity, 
suggesting that small-area mapping may be particularly useful in such areas.
134
  As well as 
these potential uses it also has the possibility of improving translatability of health 
information for new commissioners.   
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The geospatial study was based in Tower Hamlets only.  Geographically Tower Hamlets is 
a well known inner-city district in the East End of London UK, known internationally for 
its vibrant street life, restaurants and culture, and also for its socio-economic deprivation 
and poor health outcomes.  Tower Hamlets is home to a large British-Bangladeshi 
population and to more recent migrants from Africa and to a white British working class 
population.  The borough includes significant pockets of deprivation, mainly in high-rise 
estates, alongside pockets of affluence such as riverside suburbs in the South and parkside 
ones in the North.  Tower Hamlets thus exemplifies the challenges facing providers and 
commissioners planning for culturally diverse and disadvantaged populations in inner city 
urban areas.   
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Aim of the geospatial study 
 
To explore the feasibility of producing small area geospatial maps of chronic disease risk 
for use by clinical commissioning groups and public health teams.   
 
The research question was:  
Is it feasible to map geospatially an entire population’s risk of type 2 diabetes in a way that 
could lead to engagement of commissioners on the usefulness and applicability of the 
findings? 
 
Objectives 
1. To map the percentage of people at high risk of type 2 diabetes for each Lower 
Super Output Area in Tower Hamlets.   
2. To compare geospatially the percentage of people at high risk with deprivation, 
ethnicity and selected social and environmental determinants of health.   
3. To trial several different mapping methods.   
4. To compare modern maps of disease risk with historical maps of poverty.   
5. To assess the feasibility of producing maps.   
6. To consider the extent to which such information would be useful to clinical 
commissioners and local authorities engaged in neighbourhood regeneration.   
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Initially I had hoped that geospatial mapping would be possible for all 519,288 electronic 
records in the cross-sectional study.  However, it transpired that due to complex data 
sharing agreements between general practices, PCTs and CEG, individual patient postcodes 
were only available to be downloaded from general practices in Tower Hamlets.  This was 
a disappointment as having worked in the region I was aware that Tower Hamlets was often 
perceived as the area with the most investment.  To help rectify this imbalance towards 
Tower Hamlets I was able to produce one map at general practice (rather than patient) level 
which covered the whole region and this was used as the flagship map on the front page of 
the CEG special report.
109
  The focus on Tower Hamlets did, however, allow separation of 
the cross-sectional study from the geospatial study and has resulted in a more in-depth 
analysis of small area mapping.  The aims and objectives were refined as this part of the 
research progressed.  For publication in BMJ Open, the findings were framed within the 
paradigm of chronic disease risk to make the results more widely applicable, and to build 
on the United Nations summit on chronic diseases which took place during the course of 
the research.  A particular focus of the study was to identify the practicalities and 
information governance hurdles around the secondary uses of general practice data at a 
time when local general practice led commissioning groups were being established.  It 
transpired that there were a number of information governance hurdles, which are discussed 
in Chapter 8.   
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Methods 
 
Two complementary data sources were used: postcode with clinical risk factors for 
individual residents of Tower Hamlets, drawn from primary care electronic records; and 
social and environmental determinants of health, drawn from local authority registers and 
nationally available data at lower super output area level (relating to around 400 
households/1,000-1,500 people) or middle super output area (around 2,000 
households/5,000-7,200 people).   
 
Using the electronic general practice record system, a cohort was identified comprising all 
non-diabetic individuals aged 25-79 years in Tower Hamlets from 35 out of 36 general 
practices that used the same computer system.  Data download was carried out on the CEG 
secure N3 networks (which only authorised third parties and NHS organisations can use).  
In order to overcome the information governance hurdle of preventing postcode linking to 
clinical variables it was necessary to first download clinical variables attached to a 
pseudonymised identifier (n=163,275 – ‘dataset 1’).  And then, postcode was downloaded 
separately attached to the same pseudonymised identifier (n=159,353 – ‘dataset 2’).  The 
reduction in numbers was due to two practices that could not share postcode for technical 
reasons.  We converted Tower Hamlets postcode districts (n = 8,911) to lower super output 
area (n=130) using an electronic lookup table.
135
  Dataset 2 (with lower superoutput area, 
but without postcode) was linked using the pseudonymised identifier to dataset 1.  Thus, 
each individual record in the final dataset comprised a set of individual-level clinical risk 
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factors plus a lower super output area level indicator of geographical locality which could 
be related to local and nationally available statistics.   
 
The local authority dataset, extracted at middle super output area, comprised: [a] fast food 
outlets per capita (n=371), [b] green spaces per square kilometre, and [c] population density 
per square kilometre.  Fast food outlets were identified using local authority registry data 
for codes X15 ‘takeaway’ and X17 ‘restaurants’.  All X17 codes were manually reviewed 
by Dr Dianna Smith (DS) and I, and premises unlikely to serve fast food as a major part of 
their business based on their registration details were removed.  This step was necessary 
because large corporate fast food chains such as McDonalds were registered as ‘restaurants’ 
rather than ‘takeaways’.  Green spaces were quantified at the lower super output area level 
using the Generalised Land Use Database from 2005, which provides data on the area (in 
square kilometres) in each lower super output area dedicated to public green space.  This 
did not include private gardens.
136
  Population density was defined as the total population 
size of the middle super output area divided by the area in square kilometres.  This was 
calculated from the Office for National Statistics (ONS) mid-year population estimates for 
2010, the most recent available.   
 
For each individual in the final dataset, 10-year risk of diabetes was estimated using the 
QDScore.
54
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There was no previous methodology that could be found for describing how chronic disease 
risk from an entire borough’s set of primary care electronic records should be displayed by 
lower super output area.  Methodological principles were therefore applied from other 
relevant research.
122
  Determining how to display and group data, such as using deciles 
versus quintiles or percentage at risk versus median risk score (as QDScore was not 
normally distributed as described in Chapter 6) required consultation and consensus-
building with relevant local partners including: academics, general practitioners and the 
director of public health.  The final selection of display formats reflected what these 
consultees considered the most meaningful framings of the data.   
 
Three different geospatial mapping techniques were employed using ArcGIS version 9.2
137
 
and Adobe Illustrator version 10.  In the ‘basic’ (choropleth style) maps the high-risk (10 
year risk of ≥20%) population was displayed by lower super output area as a proportion of 
the denominator (non-diabetic adults aged 25-79 years).  A basic map was also created of 
the Index of Multiple Deprivation score 2010
106
 to allow a visual comparison between high 
risk of type 2 diabetes and a different indicator of deprivation than that used within the 
QDScore.  Statistical analysis of correlation was not performed due to an unquantified 
degree of colinearity between Townsend score which is used in the QDScore and Index of 
Multiple Deprivation.  Basic maps thus presented the data as geographically defined lower 
super output areas (typically defined by street blocks) in different shades of colour.  A list 
of GP practices and hospitals were located using their postcode.  They were located in GIS 
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using the centre of each postcode.  This analysis was performed to demonstrate the 
potential usefulness of informing local practice geographical needs assessment.   
 
The ‘heat maps’ assigned the proportion at high risk to the population-weighted centroid 
for each lower super output area.  A Kriging procedure was used to create an interpolated 
surface of risk.
138
  Kriging estimates the value of risk between data points where the value 
of risk is known.  In lay terms, it uses all the values for each small area on a map and 
estimates values between these points.  In effect this creates more data points on a map and 
allows finer detail to be plotted.  One use of the Kriging procedure is to create a heat map 
which shows a gradation of risk from low to high along a spectrum of colours.  Heat maps 
offer a statistically ‘smoothed’ presentation of data in which the lower super output area 
blocks are no longer visible.  One heat map for all three PCT areas was produced using data 
at the level of general practices.  For this, the EMIS code of each general practice was used 
to identify all registered people aged 25-79 years at high risk of diabetes as the numerator, 
and all people aged 25-79 years without diabetes as the denominator, therefore calculating a 
proportion at high risk for each general practice.  This enabled geospatially mapping high 
risk of diabetes across a larger area, including Tower Hamlets, Newham and City & 
Hackney.  In total 519,288 records were used for this one map across 135/145 practices.  
The postcode of each general practice was used with a recent ONS postcode look-up table 
(August 2010) which identified an exact location in space for the general practice with a 
grid reference.  One general practice’s postcode did not have a grid reference as it was a 
new build.  For this practice we used an adjacent postcode to locate a grid reference.  
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Several practices (n=20) had the same postcode.  For these the final digit of the x + y co-
ordinate was changed by 1 so that they could be separated in space by approximately 3 
metres.  Proportions of high risk individuals per practice (n=135) was mapped using a 
Kriging procedure.    
 
The ‘ring maps’ are a relatively new technique which allows factors of interest (such as 
putative environmental determinants) to be displayed circumferentially around a map.
121
  
To produce these, data was aggregated to the level of middle super output area (n=31) and 
presented as quintiles of risk.  The following data were assembled for each middle super 
output area: [a] fast food outlets per capita, [b] percentage of non-green space, and [c] 
population density per square kilometre.  Using a validated adjustment procedure,
121
 each 
was divided into highest quartile, middle 50% (2
nd
 and 3
rd
 quartiles), and lowest quartile.  
The ring map thus gives a less granular picture of the geographical distribution of a variable 
but allows additional mapping of factors that might influence this variable in each locality.  
A second ring map displaying South Asian ethnicity and unemployment score from the 
IMD was also created using a similar technique.  This was a less valid method because of 
overlap and colinearity with the variables of the QDScore, but was created during 
exploration of this method of mapping.   
 
A final analysis was undertaken using the maps of high risk of diabetes and deprivation, 
and compared to Charles Booth’s historical maps of poverty in the East End of London.139  
Given that significant urban change had occurred since the 114 years between the historical 
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and modern maps, and differences in scales and methods, this simple analysis was limited 
to visual inspection of the maps and circling of areas with persistent health risks.   
 
The whole exploratory geospatial study was made possible by a number of key partnerships 
between QMUL, general practices and the PCT.  These were similar to those for the cross-
sectional study described in Section 3.  For the geospatial study there was a new link to the 
Department of Geography at QMUL.   
 
Because of the extraction of postcodes specific permissions were requested for this part of 
the research.  The study was classed as service ‘audit’ and deemed outwith its remit by the 
local NHS Research Ethics Committee.  The local information governance group 
representing the general practices at the PCT agreed to the study, and advice on data 
handling and mapping was also sought from the NIGB.   
 
The tasks of identifying, extracting, manipulating, sharing, summarising and presenting the 
data, presented complex practical, technical and information governance challenges.  To 
capture these, a dataset was collected comprising documents (protocols, service level 
agreements, agendas and minutes of meetings), and correspondence (letters, emails, notes 
of telephone calls).  Those represented in this dataset included the NHS Research and 
Ethics Board, University Departments, Tower Hamlets PCT, local general practitioners and 
public health specialists, and the NIGB.   
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This dataset was analyzed by applying a theoretical framework developed previously to 
study the complex organisational, social and political issues involved in introducing a 
nationally shared electronic medical record.
140
  Specifically considered was: [a] information 
governance challenges, [b] practical challenges, such as the ease with which procedures 
could actually be carried out, and [c] technical challenges including issues of data security, 
downloading and interoperability.   
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Chapter 8: Results and Discussion 
 
Results 
 
Completeness of general practice records in the selected cohort aged 25-79 years without 
diabetes that should have been routinely collected (dataset 1, n=163,275 – excluding 187 
where patient permission was withheld) was as follows: age (100%), gender (100%), 
ethnicity (92.1%), Townsend deprivation score (99.7%), BMI (76.4%), and smoking status 
(96.3%).  Other variables were only recorded if positive.  [Table 11] 
 
Variable Positive (% & number) 
Family history of diabetes 21.5  (n=127,995) 
Personal history of cardiovascular disease 1.8  (n=2,972) 
Treated hypertension 5.1  (n=8,244) 
Current corticosteroid usage 0.5 (n=833) 
Table 11: Completeness of variable recording in geospatial study 
 
Records could not be generated or were removed if: [a] The general practice was not able to 
share the data for technical reasons (n=3,922) or patient permission was withheld (n=187), 
[b] the individual record contained no postcode (n=29) or lower super output area was not 
calculable from the available postcode (n=275), [c] the geographic location was outside 
Tower Hamlets (n=1,813), or [d] there was a mismatch between records in set 1 and set 2 
(n=4).  This left 157,045 records for analysis (96.2%) representing 33 out of 36 general 
practices.   
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Reducing the list of restaurants to those with a major business purpose of takeaway food 
resulted in a total sample of 371 outlets, shown in Table 12 below.   
 
Reason removed 895 (Codes X15 + X17) 
Removed no postcode 62 
Removed as staff restaurant, kitchen or 
canteen 
142 
Removed as usage unclear 74 
Removed as Cafe 149 
Removed as Bar 8 
Removed as Restaurant 88 
Removed as closed 1 
Final included 371 
Table 12: Fast food restaurants flow of data 
 
Of the data which was used in the mapping (n=157,045) 9.48% of people (n=14,885) were 
at high risk of developing type 2 diabetes within ten years.   
 
The basic Map 1 illustrates the variation in prevalence of high diabetes risk across lower 
super output areas in Tower Hamlets, with a maximum of 17.3% of the non-diabetic 
population being at high risk.  General practices and hospitals are also shown.  The areas of 
highest prevalence for diabetes risk were distributed on either side of the main east-west 
road (the A11) which transects the borough and corresponds with well-known deprived 
housing estates and high-rise blocks of flats on either side of this road.   
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Map 1: Percentage at high risk of type 2 diabetes by lower super output area 
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The basic Map 2 of IMD scores by lower super output area showed a near-identical 
geographical distribution with high diabetes risk.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Map 2: Index of Multiple Deprivation 2010 by lower super output area 
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The heat Map 3 shows the same information as in Map 1 but displayed as a globally 
smoothed surface over the entire geographic area.  The prevalence of high diabetes risk in 
this smoothed version of the data varied from 5.1 to 13.8%.   
 
Map 3: Percentage at high risk of type 2 diabetes (heat map) 
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Visualising the data as in Map 3 depicts – somewhat more dramatically – a high-risk ‘hot’ 
band running west to east through the deprived housing estates and much lower-risk ‘cool’ 
areas in the more affluent riverside in the south and park-side in the north of the borough.  
The heat map is free from the visual lower super output area administrative boundaries that 
are commonly used in maps of the basic type.  The resulting map is likely more intuitive 
for users to interpret due to the colour scheme and there are no boundaries to disrupt the 
visualisation of diabetes risk.   
 
A second heat Map 4 shows the same technique but only for the South Asian at high risk 
population.  It had been hoped that this would illustrate the finding that the South Asian 
population were at higher risk overall in most areas.  However, the technique used to create 
the heat maps did not allow for the same colours to be applied to the same values between 
Map 3 and Map 4, and so this comparison could not be made visually.  The result was the 
finding that the prevalence of high type 2 diabetes risk for the South Asian population was 
concentrated more in the West of the borough.  It should be noted that the scale on Map 4 is 
9.5-23.7% as compared to 5.1 to 13.8% on Map 3 of the population overall.   
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Map 4: Percentage South Asians at high risk of type 2 diabetes (heat map) 
Map 5 and Map 6 show the prevalence of high type 2 diabetes risk overall and in the South 
Asian population only across lower super output areas using the basic map technique.  This 
method allowed the same colours to be allocated to the same values, with the exception of 
the fifth quintile which differs in the South Asian population as prevalence extends to 
30.3%.  These two maps, unlike the two heat maps, made the finding of higher risk in the 
South Asian population visually compelling.   
 130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Map 5: Percentage at high risk of type 2 diabetes by lower super output area (2) 
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Map 6: Percentage at high risk of type 2 diabetes by lower super output area (South 
Asian population only) 
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The ring Map 7 shows prevalence of high diabetes risk by middle super output area.  In this 
depiction of the data, prevalence of diabetes risk ranges from 3.8 to 13.7%.  Each middle 
super output area is shown linked to a band of three social and environmental indicators 
which are often suggested to influence poorer health.
141
  These are (from the inside out) fast 
food outlets per head of population, percentage of non-green space and population density 
per square kilometre.  A second ring Map 8 was created without %non-greenspace, and 
added South Asian ethnicity and unemployment (derived from the IMD).  This had a 
similar visual effect, but was not regarded as robust as Map 7 because of colinearity linked 
to ethnicity and unemployment (which is measured within IMD and Townsend score which 
is within the QDScore).   
 
Overall, the ring maps provided a striking visual display of type 2 diabetes risk in the areas 
which corresponded to known deprivation and the ring provided a relatively new way of 
displaying social and environmental determinants of health at a small area level.  The ring 
provides a dashboard of indicators of wider determinants of health that appeared most 
useful when locally applied to specific population groups of 5,000-7,200 persons.  It 
demonstrates the sort of putative environmental determinants that public health specialists 
may want to map as part of routine health needs assessment to inform interventions at small 
area level.   
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Map 7: Ring map highlighting links to selected determinants of health 
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Map 8: Ring map highlighting links to selected determinants of health (2) 
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Map 9 shows the proportion of people at the level of an individual general practice at high 
risk of developing type 2 diabetes within ten years.  The prevalence of high diabetes risk 
varied from 4.1 - 16.7% across all three boroughs from the cross-sectional study.  This 
revealed a band of risk, which could be called the ‘East London Diabetes Belt’.   
 
This belt of risk stretches from Tower Hamlets in the west, with a high Bangladeshi 
population, to north-east Newham, where there is a high percentage of South Asian and 
Black African ethnic groups.  Affluent riverside properties in the South and parkside 
residences in the north show low levels of type 2 diabetes risk.   
 
The ‘East London Diabetes Belt’ is similar to the ‘Diabetes belt’ in the Southern States of 
America.
127
  This has high potential to inform the work of commissioners, with a view to 
taking action to reduce incidence of type 2 diabetes through locality-based interventions.  In 
some areas, almost 1 in 6 adults fell into the ‘high risk’ category.   
 136 
 
 
 
 
 
Map 9: Percentage of patients at high risk of type 2 diabetes by general practice – The 
‘East London Diabetes Belt’ (heat map) 
 
Map 10 shows Charles Booth’s historical map of poverty in London from the late 1800s, 
which was created using subjective judgements of poverty based on direct observation.   
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Map 10: Charles Booth’s map of historical poverty in London in the late 1800s 
Map 11 shows a sequence of four maps.  First, Map 1 of high risk of diabetes and Map 2 of 
IMD showing the overlap between risk and deprivation.  Second, Map 1 is compared to 
Map 10.  A simple circling technique reveals that there are similarities between areas of 
poverty in the late 1800s and areas of high risk of diabetes (proxy for deprivation) in 2011.   
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Map 11: Comparison with historical maps of poverty 
 139 
 
This final analysis highlights an important message: despite changing social determinants 
of health and vastly different relative levels of poverty, a few geographical hotspots of 
particular need appear to have remained constant.   
 
As was anticipated, the information governance challenges were substantial and were as 
time consuming as the technical ones.  In order to access the data (including postcodes) 
from general practice records, permission had to be obtained from both the local 
information governance committee of the PCT and the NIGB. In addition, because this 
project had a research element, it also required advice from the local NHS Research Ethics 
Committee and from the university’s Research and Development Office (who both deemed 
the project ‘audit’).  Potentially identifiable data from patient records had to be handled 
securely under a protocol advised by the NIGB.  This kept postcode information separate 
from clinical variables with pseudonymised conversion to lower super output area.   
 
Information governance issues were therefore time-consuming and required specialised 
knowledge and formal permissions, but they were not insurmountable.  Furthermore, the 
process of establishing a procedure for the current project built a stock of knowledge and a 
network of contacts which would make any subsequent set of permissions and procedures 
substantially easier to set up.   
 
The practical challenges of undertaking this work were relatively minor. However, this was 
probably due to a near-optimal local infrastructure.  Unusually, there was access to a single 
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electronic database covering an entire PCT area, due to unique data sharing arrangements 
between the local general practices, the PCT and the university.  Furthermore, the quality 
and completeness of general practice electronic data across the borough was high.  Those 
seeking to replicate this approach in other parts of the country may need to undertake 
groundwork to establish a mechanism for data extraction from multiple different computer 
systems, underpinned by relationships and permission for governance, data sharing and 
data quality.   
 
Technical challenges included downloading and cleaning the data, which had to be done in 
several stages due to the size of the files and handling of multiple variables.  Conversion of 
postcode to lower super output area with look-up tables and secure data pairing protocols 
between datasets 1 and 2 was time consuming.  Specialist software was expensive and 
different versions used between CEG and the Geography Department was inconvenient and 
resulted in time spent converting files and reducing lines of data, with older software 
unable to hold as much data.   EMIS Web does not keep records of searches performed 
once an update is installed (which occurs every 4-6 months), so there is a limited time 
window for cross-sectional analysis.   
 
All geographical work was carried out on a 256-bit NHS encrypted memory stick in the 
Geography laboratory so that files with lines of patient information were never used outside 
the CEG except on secure memory sticks.  This was time consuming and prevented regular 
backup of data, which had to be done between two encrypted memory sticks periodically.  
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The technical process of mapping was relatively straightforward - once the data had been 
prepared, received and decisions made about what maps to create - as I had the expertise of 
DS to use GIS and Adobe Illustrator.  It is unlikely that without these skills high quality 
maps could have been produced.   
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Discussion 
 
In this study, it was possible to: [a] obtain a near-complete set of de-identified data drawn 
from an entire borough’s electronic primary care records in an ethnically and socio-
economically diverse inner city district, [b] use a computer algorithm to determine ten year 
risk of type 2 diabetes for individuals on this dataset, and [c] use geospatial mapping to 
highlight dramatic variation in diabetes risk by small area geography and show how social 
and environmental determinants of health can be effectively displayed and communicated.  
Information governance and technical issues were challenging but surmountable.  The 
technique of geospatial mapping, as explored through three different formats, may help to 
meet the rapidly growing need for local health intelligence by planners and commissioners 
of health services.   
 
Taking a geospatial view of health information such as population at risk of disease 
complements a traditional statistical approach to such data.  Epidemiologists use statistical 
tests, arithmetic adjustments, and critique causality claims and data.  By contrast 
cartographers use geospatial visualisation, utilise classing breaks (e.g. quintiles), and 
critique symbolisation.
122
  These different paradigms have an important complementary 
role.  Quantitative analysis identifies statistically significant trends; cartography brings 
meaning and local relevance.  Yet merely converting routine epidemiological data into 
maps runs the risk of oversimplifying complex data and misunderstands the purpose of 
geovisualisation, which is to represent data spatially.  Grouping and classing data for 
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mapping is an interpretive process, and ‘points of interest’ to which the eye is drawn on a 
map may or may not correspond to statistically significant relationships between variables 
as determined by traditional epidemiological approaches.   
 
The key aim in health mapping is not to identify statistically significant relationships, but to 
gain firstly insight, then understanding, of the ways in which health status varies over 
space, and to reveal the potential drivers behind this variation.  In this research, by 
identifying areas of highest prevalence of high diabetes risk by small geographical areas, 
local general practitioners, public health specialists and planners can be aware of increased 
risk and possible causes in their locality, so as to target individual and population 
interventions.  Such ‘local’ information may be unlikely to emerge from statistical analyses 
alone.  
 
Individual health is also linked to non-spatial social determinants, and a map of local-level 
data is most valuable when interpreted in the wider social context. Relative income 
inequality within the UK is likely to influence weight (and therefore diabetes) via complex 
pathways.
142
  One example is the ‘obesogenic environment’ model which encompasses 
local and national, physical and social environments.
143
  The maps presented here are 
ideally considered with this context in mind.   
 
Resources and skills in handling health information in order to commission new 
interventions and services may be limited, particularly where they relate to dual 
 144 
 
responsibility of both local authorities and health providers for the health of local 
populations.  Geospatial mapping offers one option to address these deficiencies and 
present diverse information about health and its wider determinants in an accessible format 
to support commissioning and planning expertise.  It is possible, though somewhat 
speculative at this stage, that investment in the skill base needed for this approach may be 
cost effective in the longer term.  
 
The mapping study is probably one of the first to use routinely collected, local individual 
electronic patient data to generate high-quality small-area maps of disease risk across an 
entire borough.  A significant strength of the study was the quality and completeness of the 
dataset from which the geospatial maps were derived.  There was up-to-date data on the 
majority of the target cohort (aged 25-79 years) across the whole of Tower Hamlets.   
 
The completeness of data capture in the study was attributable to a number of things 
(similar to that for the cross-sectional study except that in Tower Hamlets all these 
relationships were generally considered to be stronger and more fully developed): [a] 
existing partnerships between the university and the NHS, [b] a 20 year history of using 
electronic medical records in local general practices, with standard data entry templates for 
performance monitoring, audit and needs assessment, [c] existence of local data sharing 
agreements and information governance infrastructure for overseeing the use of electronic 
personal medical data, and [d] the fact that 35 out of 36 general practices in the borough 
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used the same computer system (EMIS) which was compatible with the chosen diabetes 
risk algorithm (QDScore), and 33 out of 35 shared postcode.   
 
A potential limitation of the study is this uniqueness of the local context.  In order for the 
method used here to be successfully reproduced by others, a number of conditions need to 
be met.  First, effective data sharing agreements must be in place and a high degree of trust 
is necessary between all parties.  Second, the general practice records of a whole population 
need to be accessible and the quality of relevant data fields on these records (completeness, 
accuracy and consistency of coding) must be high.  Third, the method requires that patients 
registered at a particular general practice live in the same district.  This was not the case for 
1,813 (1.1%) individuals in this study.  In some other localities this discrepancy might be 
far greater.  Fourth, the task of downloading and cleaning data and geographically mapping 
disease risk required an advanced set of skills and took many hours of input from a data 
analyst (RM), public health specialist (DN) and human geographer (DS).  It is some way 
off for a set-up whereby planners or general practitioners can simply hit the ‘map it’ button 
on their consoles to produce maps like the ones illustrated in this thesis.   
 
Two areas in this study produced much further discussion with colleagues and I regard 
them as special interest topics: [a] information governance issues associated with geospatial 
mapping, and [b] how the media interpreted the findings from the maps.   
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Information governance and geospatial mapping 
 
Changes in the technical infrastructure of general practitioner electronic patient records 
create the potential for analysis of previously unavailable individual health data for research 
and audit.  Such ‘secondary uses’ of data collected largely or wholly for the purpose of 
individual patient care raise substantial technical, security, ethical and civil liberties issues.  
Concern about protecting patient data is central to information governance in the NHS.  
With the increasing non-standardised use of mapping for data analysis and presentation to 
commissioners, new information governance challenges are emerging.   
 
During the course of preparing the geospatial maps advice supplied by the NIGB was 
followed on how to handle health data for small numbers of people, so as to protect against 
any person being identified.   However, there were specific issues about how to conceal 
small numbers of persons in one of the maps.  This was resolved after a meeting with the 
NIGB, but it revealed that specific published guidance on protecting people from being 
identified through geospatial mapping were lacking, and many rules of thumb were being 
used.  I decided with my colleagues to write a detailed academic paper with the NIGB on 
these information governance issues and include the techniques that could be used to 
protect against identifying people in geospatial maps, and develop an assessment of risk 
framework for researchers to use.  This academic paper has been submitted to the journal 
BMC Public Health and is included as Appendix 7.  Although I conceptualised the idea for 
this paper, brought the authors together and produced the first draft, DS, the geographer I 
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had been working with, took the lead on developing the manuscript and themes contained 
within.  Below is a description of some of the early issues that led on to the much more 
detailed piece of work with a group of experts in the academic paper.  I hope the paper may 
eventually be used as the basis for a government endorsed guideline for researchers.   
 
When data is aggregated to small areas (often lower super output areas in England), there 
may still exist a potential breach of data protection if the number of individuals within an 
area are below a threshold number.  Techniques to handle this problem can be applied from 
confidentiality guidance for small area data and health statistics which despite being 
primarily intended for statistical tables have the potential to be applied to geospatial 
maps.
144 145
  
 
Firstly, it is important to determine a threshold number of subjects likely to be identifiable 
in any one area based on the condition being studied (e.g. 3, 5 or 10) and use a denominator 
as large as possible for creating the map.  Once map creation has taken place several 
possibilities exist for suppressing cells that fall below the threshold: [a] leaving cells blank 
(care needs to be taken to ensure that the number cannot be calculated from other cells by 
differencing, although this is less likely to be significant in maps where quintiles and ranges 
are more commonly used), [b] amalgamation of adjacent cells such that numbers rise above 
the pre-determined threshold, [c] rounding small numbers up to the threshold or moving up 
to the next geographical level (although this may significantly change the resulting map), 
and [d] using ranges of numbers or percentages, for example, converting 3 to 0-10.   
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Map specific problems need to be borne in mind.  For example, suppressing a geographical 
cell by colouring it white or marking it with an X is more complex than the equivalent 
manoeuvre in a data table, since it draws attention to the fact that small numbers are present 
in that geographical location.   
 
Other guiding principles could include: [a] an assessment of the sensitivity of the data, [b] 
who will ultimately have access to the maps, [c] whether individual people could 
reasonably be identified, and [d] searching for other maps of the same data and considering 
whether small numbers could be calculated by differencing or a similar technique.  
Additionally, even if it is intended that maps will only be available amongst health service 
planners, the potential of maps to become publicly available once they have been 
transferred electronically between different parties is high.  Because of their highly visual 
nature compared to data tables, extra caution in electronic transfer of maps should be 
applied.   
 
Information governance issues in mapping become especially sensitive when the unit of 
analysis is small, the number of affected individuals is small (making it a real possibility 
that someone could be identified), and the condition is sensitive or stigmatising (e.g. 
teenage pregnancy or mental health).  Possible solutions exist but there are no agreed 
standards.   
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The necessity of geovisualisation for data display is growing with the shifting structure of 
the NHS, and a standardised and regulated approach to creating maps of health data would 
allow for greater consistency in outputs, aiding interpretation between user groups and 
suborganisations, as well as protecting patient confidentiality.  In the absence of formal 
guidelines for governance of mapping, there is a risk that case law (which is likely to 
accumulate via atypical and highly sensitive cases) will determine the use of geospatial 
maps for health planning purposes.  The research community should urgently seek to 
rectify this potential gap of comprehensive published guidance on how to handle patient 
level data for geospatial maps.   
 
A more detailed and refined discussion of these issues and further themes relevant to this 
area can be found in Appendix 7.   
 
How the media interpreted the findings from the maps 
 
Having worked at the Department of Health with the Chief Medical Officer I had acquired 
some experience previously of working with the media, including: [a] how to prepare a 
press release, [b] thinking through how the media would interpret reports, research and 
press releases, and [c] preparing lines to take prior to interviews to ensure that the 
interviewee stays on message and is not deflected into making a mistake or falling into the 
trap of inadvertently providing journalists with a sensational (and often inaccurate) 
headline.   
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I had not initially thought about how this experience would play out during my academic 
attachment at QMUL.  Following the publication of the systematic review, Professor 
Greenhalgh suggested preparing a press release.  This was slightly delayed as the BMJ 
published the paper without telling us in advance and so the press release was issued on the 
day of publication, which attracted little interest as journalists prefer to run the story the 
same day as the paper is released.   
 
This had, however, whetted my appetite for applying previously learned media skills in an 
academic context, and I was keen to try and do this with the geospatial study.  I thought it 
might make a news story if we were to publish the BMJ Open paper of the geospatial maps 
and the special report on diabetes risk from CEG on the same day.  I suspected this would 
be difficult to coordinate, yet wondered whether it might be of media interest as there 
would be a combination of a ‘British Medical Journal’ publication and an in-depth report 
from the ‘East end of London’ revealing a very high level of risk of diabetes.   
 
I met with the press officer (Kerry Noble) with whom I had worked to produce the press 
release on the systematic review.  She agreed that the story was of interest, and appreciated 
my desire to highlight risk of diabetes in the East end to help with preventive efforts, but 
felt it was lacking an interesting enough angle to achieve pick-up from the major national 
news providers.   
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I needed a fresh approach to the research findings.  As I had been walking to work at the 
university that day to meet the press officer, I had an idea which eventually resulted in a 
flurry of national media interest in maps of diabetes risk in the East end of London.   
 
I live in Bow, in Tower Hamlets (in a lower super output area with a risk of type 2 diabetes 
of 0.0-5.4%).  Most days I walk down the well known A11 for about 2 miles to work at the 
university or PCT.  This road is better known by its formal names, being called Bow Road, 
becoming Mile End Road, then Whitechapel Road, and finally Aldgate High Street.  There 
was apparently a suggestion to rename it the Olympic Boulevard as it is the main route 
from The City of London to the London 2012 Olympic Site.  Each time I walk down that 
road I am reminded of the deep inequalities and health problems inherent to life in the East 
end.  The North side of Bow Road and Mile End Road are well known for affluent terraced 
housing epitomised by Tredegar Square.  The South side has highly deprived high rises and 
housing estates.  From Mile End Road and onto the early part of Whitechapel Road both 
sides of the road are awash with small fast food takeaways (mostly deep fried chicken), 
although there is one Subway, and two Nandos, but no other chain restaurants.  On this part 
of the road both sides contain highly deprived housing, with the occasional pocket of 
private housing.  Many people (sometimes I think most) are smoking.  Often I will walk 
past a group of people on the street drinking super strength lager out of cans, and others 
who appear to be homeless.   
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Visually the ethnic diversity is striking.  For example, in addition to the diverse daily 
market on Whitechapel Road, I sometimes overhear four or five different languages being 
spoken on one journey.  Mosques lie tucked away behind unremarkable shop-like 
entrances, and there is often a loud Christian street preacher outside Mile End or 
Whitechapel tube stations.   
 
At the start of Whitechapel Road there are two statues in quick succession in honour of the 
famous reformer, missionary, and founder of the Salvation Army, William Booth.   As I 
walked past these two statues on a cold day in January 2012 on my way to meet the press 
officer, I was reminded of one of the other famous ‘Booths’, Charles Booth, who had 
created well-known maps of poverty in London in the late 1800s.  This gave me an idea.  
What if there was a similarity between the areas of diabetes risk and poverty that we had 
revealed and the historical maps of poverty from the late 1800s.  I thought this could well 
be a hook that the media would latch onto and provide the platform to discuss risk of 
diabetes today.   
 
With the help of the press office we obtained the Booth maps from the London School of 
Economics
139
 and there was indeed visual similarity between areas of historical poverty and 
modern day deprivation and risk of diabetes.  The comparison was slightly tenuous.  The 
scales of the maps were not exactly the same, the Docklands had far fewer residential 
properties in Victorian times, and the methods used were very different (observation versus 
highly sophisticated electronic spatial analysis).  Yet, despite these limitations a pattern was 
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evident and after discussion with colleagues I decided to use the Booth map comparison to 
highlight modern day risk of diabetes.   The press officer was in favour, and drafted a press  
release
146
 which I edited.  It is shown in Box 2 below: 
Modern health mapping shows how poverty and ill health persist over 100 years 
 
Researchers from Queen Mary, University of London are aiming to improve the health of 
Londoners by combining a century-old mapping technique with up-to-the-minute 
technology. 
 
Using type 2 diabetes as their example, the researchers have compiled detailed maps of 
east London highlighting the geographical ‘hotspots’ of disease risk. 
 
The maps, which are published today in BMJ Open reveal startling similarities to the 
renowned ‘poverty maps’ created in the late 19th Century by Victorian reformist, Charles 
Booth. 
 
The researchers chose to study type 2 diabetes risk because it has well-known risk factors 
and is preventable. It is strongly associated with poverty and South Asian ethnicity, both of 
which are common in east London today. 
 
The aim of the project is to help local authority and NHS services to tackle poor health by 
directing efforts where they are most needed. Although the study examined the London 
boroughs of Tower Hamlets, Hackney and Newham, the researchers say that the same 
technique could be applied anywhere in the country, and to other diseases. 
 
Unlike the Booth maps which were based on observation, the new study uses an entire set 
of electronic records from GP surgeries in the area. This very precise information means 
that the maps are much more accurate and will be useful to individual GP surgeries. 
 
Electronic records from over half a million people were included in the research. Each was 
assessed for risk of developing diabetes using a well-established prediction tool, the 
QDScore.  
 
People were categorised as ‘high-risk’ if they were found to have a one in five or greater 
risk of developing diabetes within ten years. 
 
Overall around ten per cent of the adult population fell into the high-risk category. 
However the maps showed ‘hotspots’ where up to 17 per cent were at high risk. Further 
analysis showed that these hotspots were associated with areas of poverty.  
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Box 2: QMUL press release on diabetes risk Feb 2012 
These hotspots were surprisingly similar to areas of poverty highlighted in Booth’s maps 
from over 100 years ago. 
 
The study was led by Douglas Noble, a Public Health Doctor and Lecturer at Barts and 
The London Medical School, Queen Mary, University of London, and published in BMJ 
Open with additional material in a full report aimed at the NHS and Public Health 
specialists.  
 
Dr Noble said: “It was no surprise to see that diabetes risk is high in areas where poverty 
was high. What was surprising was that some of these pockets of deprivation and ill-health 
have persisted for over 100 years.  
 
“But unlike in Booth’s time, we now know how diseases like diabetes can be prevented. 
Using electronic records to create maps like these throughout the country could improve 
health and save money for the NHS. 
 
“When you think of what life was like in the East End in the late 1800s it’s extraordinary 
what the NHS and public health professionals have achieved, often with limited resources.  
But there’s more still to do, and we hope this detailed information will help to reduce risk 
of diseases like diabetes” 
 
The research also looked at known risk factors and could show where a lack of green space 
or a proliferation of fast food outlets could be contributing to ill-health. 
 
Trisha Greenhalgh, Professor of Primary Health Care at Queen Mary, University of 
London, also worked on the report. She said: “Health mapping has enormous potential for 
the NHS, especially with a disease like type 2 diabetes which we know can be prevented by 
keeping a healthy weight and staying active. 
 
“This study, which concentrates on three of the ‘Olympic boroughs’, highlights the dire 
need for a major and lasting Olympic legacy to improve health and longevity in east 
London.” 
 
Steven Cummins Professor of Urban Health at Queen Mary’s School of Geography 
commented: "Population health has vastly improved over the last 100 years. However, as 
these maps starkly illustrate, a century of social, economic and physical change has failed 
to eliminate underlying geographical inequalities in disease in east London." 
 
This work was funded by Tower Hamlets, Newham, and City and Hackney primary care 
trusts and by the National Institute for Health Research. The National Information 
Governance Board advised on data protection issues.   
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I thought the release read well, although I had a slight reservation about the headline being 
solely about the historical aspect, but nevertheless I decided to go with the experience of 
the press office, on the basis that all the main information about diabetes was included 
within the release.   The BBC was the first major organisation to carry the story, shown in 
Box 3 below: 
 
Box 3: Coverage of diabetes risk research by bbc.co.uk 
Reproduced from http://www.bbc.co.uk/news/uk-england-london-17062735  
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The BBC led with the historical angle as the headline.  They included a pdf of five of the 
maps so that readers could make a comparison of the findings themselves.  The report was 
accurate and I was pleased that they covered both ethnicity and deprivation as major risk 
factors in the opening sentences, as well as the aim of informing commissioning.   The 
latter part of the article included a black and white photograph of poor looking East 
Londoners in the 19
th
 century.   
 
The next major press agency to cover the story was the Daily Mail Online
147
, shown in Box 
4 below: 
 
 
Box 4: Coverage of diabetes risk research by Daily Mail Online 
Reproduced from http://www.dailymail.co.uk/news/article-2102485/Updated-maps-
Londons-poorest-areas-epidemic-junk-food-diabetes-streets-Victorians-died-
malnutrition.html  
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This newspaper took a more sensational angle consistent with the approach of the tabloid 
press.  At first I was somewhat dismayed by the headline as it initially struck me as 
inaccurate, but after careful thought I realised that in fact it was quite a clever interpretation 
of the research findings.  Unlike the BBC the headline did not focus solely on the historical 
angle, but included information on the determinants of health.  I assume the journalist had 
studied the ring maps and noticed that in some of the areas of high diabetes risk there was 
also a preponderance of fast food restaurants.  The headline highlights the geographical 
comparison between risk factors for poverty today (fast food leading to diabetes), with risk 
factors for poverty in the Victorian Era (malnutrition leading to death).  Both themes are 
encapsulated with the prefix: ‘The changing face of poverty’.  Drawing attention to the 
paradox of lack of food and poverty historically, with too much of the wrong type of food 
and modern-day poverty was clever, eye-catching, and on-message with mainstream public 
health promotion.   
 
The article itself concentrated on this angle of the changing nature of the social 
determinants of health, and included an interesting box on the life of Charles Booth.  
Several pictures were chosen, including: two of the maps, a picture of a poor looking 
Victorian family, a Victorian street scene with poor looking children, a picture of Charles 
Booth, and a picture of modern day young people consuming fast food.  The last picture 
which was put alongside the scene of poor Victorian children is shown below in Box 5.   
 158 
 
 
Box 5: Picture from Daily Mail Online 
Reproduced from http://www.dailymail.co.uk/news/article-2102485/Updated-maps-
Londons-poorest-areas-epidemic-junk-food-diabetes-streets-Victorians-died-
malnutrition.html  
 
Whilst the Daily Mail did mention other risk factors, the focus was mainly on fast food, 
epitomised by the right hand picture in Box 5.  It highlighted the damaging effects of a 
reversible risk factor (fast food consumption) to health through the link to development of 
diabetes.  I was pleased that a reversible risk factor was chosen by the newspaper, as it 
shows how individual choices can affect risk of diabetes.  It was also noticeable that the 
three youths pictured in Box 5 are of a lower risk ethnic group, and are not visually 
clinically obese.  This sends out a satisfactory public health promotion message i.e. you 
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don’t need to be already overweight or of a certain ethnic group to be at increased risk of 
diabetes - poor diet is a risk factor in and of itself because of the potential it has to cause 
obesity in the long term.   
 
A local newspaper called East End Life
148
 also featured the research in print (and available 
online), as did the Daily Telegraph in their print edition only.  BBC 1 London television 
covered the story on the evening regional news, and a journalist from The Economist 
interviewed me in connection with a larger piece on poverty in London to be published 
later this year.  I turned down a radio interview with BBC London Drivetime as I had 
concerns after speaking to the journalist on the telephone that they were going to focus on 
immigrants living in poverty, telling me they’d done: ‘a lot on diabetes recently’.  I felt that 
was an unhelpful angle.  Table 13 shows an analysis of the emphasis placed on various 
themes from the original press release from the news agencies that covered the research 
online.   
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Major themes QMUL Press 
Release 
bbc.co.uk Daily Mail 
Online 
East End Life 
Historical poverty +++ +++ +++ +++ 
Risk of developing 
diabetes 
+++ +++ +++ +++ 
State of the art 
mapping technique 
+++ + + ++ 
Diabetes risk factors +++ +++ +++ +++ 
Aiding 
commissioning of 
prevention 
+++ +++ ++ ++ 
Using research 
methods in other 
places 
+++ + + + 
Diabetes risk scoring +++  ++ ++ 
Primary care 
electronic records 
+++ + + + 
The Olympic 
boroughs 
+++ +++   
Geographical 
inequalities 
+++    
Fast food +  +++  
Table 13: Analysis of media coverage of diabetes risk 
 
Overall the media coverage was very good, and highlighted the major issues of risk of 
diabetes and common risk factors.  The decision to use the comparison with historical maps 
as an entry point to a wider discussion on diabetes worked well.  In Section 5 I discuss 
further how the media coverage has helped to contribute to further preventive action 
locally.   
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SECTION 5: Conclusions 
Chapter 9: Summary, implications and personal reflection 
 
Key findings 
 
Section 1 highlighted how type 2 diabetes is on the rise, with increases in prevalence 
predicted internationally, nationally, and locally.  East London faces vastly increasing rates 
of diabetes by 2020 with the number of diagnosed cases expected to rise from 
approximately 40,000 to 80,000.
109
  Risk of type 2 diabetes is closely associated with 
development of established disease and could reasonably be expected to rise by the same 
factor resulting in 1 in 5 adults at high risk of type 2 diabetes by 2020 in East London.  
Urgent public health action needs to be taken not just to improve early diagnosis and 
management of established diabetes, but to reduce risk of developing diabetes across the 
whole population.  In face of this, robust methods for identifying those at risk of diabetes 
are essential.   
 
The systematic review of diabetes risk scores in Section 2 considered the performance and 
impact of risk models and scores for predicting risk of type 2 diabetes in adults without 
known diabetes.  Results showed that there were some diabetes risk models and scores that 
could be relatively easily applied to routinely collected data, such as that contained within 
electronic primary care records.  However, out of 145 models and scores, performance and 
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impact was very mixed, with many scores not making any impact in the real world.  Much 
more work is needed to assess impact and usability in the long term.   
 
In Section 3, using one of the risk scores from Section 2 (the QDScore) on an entire 
population’s electronic primary care records, I explored how feasible it was to aggregate, 
describe, and stratify diabetes risk in a way that meaningfully informs locality-based needs 
assessment and service planning.  This was successfully done, although there were various 
hurdles, including statistical colinearity, complex data handling issues, and a lack of 
engaging presentation techniques.  The results showed that 1 in 10 adults were at high risk 
of type 2 diabetes and, in particular, there was significant association with cardiovascular 
morbidity, ethnicity and deprivation.   
 
Finally, in Section 4, research was also undertaken on the feasibility of geospatially 
mapping an entire population’s risk of type 2 diabetes in a way that could lead to 
engagement of commissioners on the usefulness and applicability of the findings.  This was 
also successful, despite information governance challenges, and judging by the media 
response, has high potential to highlight risk of type 2 diabetes to a wide audience.  Further 
more detailed formal qualitative research of impact would be a logical next step.   
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Implications for policy, practice and research 
 
Geoffrey Rose, the famous public health professor, originally prioritised population 
interventions over targeting individuals.
149-151
  Although both strategies are not in conflict, 
in response to interventions aimed at individuals of which only a few benefit, Rose 
concludes: 
150
  
 
‘We are therefore driven to consider mass approaches, of which the simplest is the 
endeavour to lower the whole distribution of the risk variable by some measure in which all 
participate.’  
 
As Rose also suggests this may result in the prevention paradox
149-151
 i.e. benefit conferred 
by the mass approach, may confer little gain for those at high risk.   
 
The Marmot review Fair Society, Healthy Lives: A Strategic Review of Health Inequalities 
in England recommended proportionate universalism for tackling health inequalities, 
defined as follows:
152
   
 
‘Focusing solely on the most disadvantaged will not reduce health inequalities sufficiently.  
To reduce the steepness of the social gradient in health, actions must be universal, but with 
a scale and intensity that is proportionate to the level of disadvantage.’ 
 
 164 
 
Applying and drawing on these two approaches to the findings in this thesis, it would 
appear that the weight of healthcare resources and public health interventions focus mainly 
on those who have established diabetes and those with undiagnosed disease.  Efforts mainly 
revolve around controlling disease, with monitoring of biochemical parameters such as 
HbA1c.  This approach alone is unable to deal with increasing prevalence.  The weight of 
public health intervention needs to shift as on the population curve shown in Figure 9.   
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Moving the focus of public health interventions to prevent diabetes 
 
By targeting those at risk of developing type 2 diabetes, disease prevention has the potential 
to reduce incidence, prevalence, morbidity, mortality, healthcare use and costs, and increase 
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quality of life.  This type of paradigm shift requires high-level health policy to drive whole 
system reform.   
 
The need to reduce the prevalence of non-communicable diseases has been recognised 
internationally by the United Nations.  The growing burden of diabetes, alongside other 
non-communicable diseases such as cardiovascular disease, respiratory disease and cancers, 
has been met with a call from the United Nations General Assembly at the 2011 United 
Nations High Level Summit on Non-Communicable Disease.   They have called for a 
strengthening of national policies and health systems, population wide interventions, 
primary care services and disease monitoring across the whole population.
153
 
 
Closer to home in the UK, the Foresight Report on obesity (the major risk factor for 
diabetes) stated: ‘...a bold whole system approach is critical – from production and 
promotion of healthy diets to redesigning the built environment to promote walking, 
together with wider cultural changes to shift societal values around food and activity.” 154 
 
More specifically in May 2011, NICE produced guidance on population and community 
interventions aimed at preventing diabetes.
13
  Further guidance, currently in draft form, also 
by NICE, specifically addresses interventions for individuals at high risk.
155
  This offers the 
possibility of shifting the focus of public health efforts towards prevention both nationally 
and locally.   
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Several principles relevant to many public health areas underpin the NICE guidance for 
populations and communities: [a] behaviour change through education, [b] emotional 
support and planning, [c] weight management through healthier eating (e.g. ‘five a day’) 
and interventions aimed at weight reduction that are measured, specific and individual, [d] 
physical activity including 30 minutes five days a week, and [e] cultural sensitivity to 
ensure that interventions take account of language and literacy, educational barriers, 
religion and cultural norms.  Eleven specific recommendations are made.  Many are 
expressed in generic terms, covering strategy, health promotion, education, physical 
activity, healthy eating and targeted prevention.  These are summarised in Table 14.   
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National recommendations National and local 
recommendations 
Local recommendations 
Working towards integration of 
strategies for all non-
communicable diseases, 
including partnership working, 
focusing on cross-cutting risk 
factors, addressing demographic 
disparities, collating basic 
epidemiology, improving 
availability of resources.   
Strategy 
Educating workers 
who have a role in 
health promotion.  
Education 
Identifying high risk communities by 
utilising routine health intelligence 
through joint strategic needs 
assessments, locating existing 
interventions, and finding community 
organisations with potential for health 
promotion functions.  Targeted 
prevention 
Promoting healthier eating habits, 
including working with the 
private sector, manufacturers, 
caterers and retailers to promote 
healthier foodstuffs.    
Healthy eating 
Delivery of culturally 
sensitive health 
promotion 
information to the 
entire population 
which tackles 
misunderstandings 
and promotes healthy 
eating and exercise.   
Health promotion 
Locally led strategy formation 
involving best use of evidence and 
local cost effectiveness knowledge, 
environmental change, and targeting 
high risk groups.  Strategy 
Promoting exercise, including 
highlighting recommended daily 
amounts, changing the built 
environment, and tracking 
progress.  Physical activity 
Specific interventions for high risk 
community groups involving 
partnership, outcome measures, 
education and training of workers from 
a range of backgrounds, and appointing 
community champions.  Targeted 
prevention 
 
Adapted and targeted national health 
promotion messages.  Health 
promotion 
Promoting healthier eating habits by 
working with local partners and 
businesses, and making information 
available about entitlement to 
discounts and menus.   
Healthy eating 
Promoting exercise, including working 
with local planning departments and 
leisure services, local employers, and 
highlighting recommended daily 
amounts.  Physical activity 
Table 14: NICE populations and communities guidance on interventions for 
preventing diabetes 
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NICE estimate that interventions costing £10 (for the whole population) and £100 (for 
Black and minority ethnic groups) per person, which returned a mean weight loss of 0.25kg 
and 1kg respectively would be cost effective at a cost per quality-adjusted life year 
threshold of £20,000.  Weight loss interventions in Black and minority ethnic groups need 
participants to lose 3-4kg to achieve fiscal savings.  This led NICE to the conclusion that 
less expensive population wide interventions have to be combined with effective individual 
interventions targeted at those at high risk.  This approach is consistent with the Marmot 
review’s recommendation of proportionate universalism i.e. in order to tackle health 
inequalities across all of society, public health action should be appropriate for everyone, 
but proportionally more for those whose need is highest.
152
  At a policy level the findings in 
this thesis offer an approach that could be used to help achieve this dual approach.  As 
summarised in Chapter 2, Black and minority ethnic groups and people from deprived areas 
have been shown to be at much greater risk of type 2 diabetes.  Electronic record analysis 
and risk scoring could allow health planners to identify both ‘locality hot-spots’, specific 
high-risk individuals and the level of risk across the entire population, with a view to 
achieving proportionate universalism.   
 
A second set of NICE guidelines specifically considering individual interventions for 
individuals at high risk is currently in draft form.
155
  The draft recommendations in this 
report consider two broad areas: [a] identification of high risk people, and [b] individual 
interventions to reduce risk.  Draft recommendations include healthy eating, physical 
activity, targeted interventions, pharmacological therapy, surgery and risk identification.  
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As described in this thesis the latter has significant potential to accurately identify high risk 
individuals, and such a system could be incorporated into the NHS Health Checks 
programme, which currently targets 40-74 year olds for an assessment of vascular disease.
43
  
This programme already includes identification of diabetes for some high risk individuals.  
Using a validated tool such as the QDScore could result in more accurate testing of high 
risk individuals for further follow-up and interventions.   
 
Figure 10 shows the clinical pathway for NHS Health Checks.
43
  It already includes a 
diabetes filter.  Replacing the current filter with the QDScore could potentially allow more 
accurate triage of high-risk individuals for further testing/interventions.  I have already 
started to take this work forward with the local PCT partners, with a view to incorporating 
QDScore in NHS Health Checks locally from the next financial year.   
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Figure 10: NHS Health Check Programme 
Reproduced from 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh
_098410.pdf  
 
Essential to using QDScore within NHS Health Checks will be its automatic incorporation 
within the electronic GP record.  This would mean locally that rather than a GP calculating 
it manually and entering every patient risk factor, EMIS Web would contain the algorithm, 
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extract the risk factors, and present the risk score directly to the GP.  This is currently under 
development.   
 
On the back of the media coverage, and with the advent of the QDScore, which has just 
recently been renamed QDiabetes, as a downloadable app on apple.com, I have begun to 
explore using it more widely locally.  This has involved early discussion around 
incorporating it on every bedside monitor in the acute hospitals.  I have also been in 
discussion with a diabetes charity, that aims to raise awareness of diabetes, and that had 
approached Tower Hamlets PCT.  They wanted to perform random point of testing for 
blood glucose around the borough to raise awareness for diabetes.  I met with them and the 
Director of Public Health, and we have suggested they use the QDScore instead to highlight 
risk, and aim to park their vans (with testing stations and accompanying health promotion 
materials) in the areas identified as high risk in the maps in this thesis.  This discussion is 
ongoing.   
 
Delivering diabetes prevention in people who are not suffering from any disease requires 
skills which traditionally-trained clinicians may not possess.
156
  Almost nothing is known 
about the reach, uptake, practical challenges, acceptability and cost of preventive 
interventions in high-risk groups in different settings.
27
  The relative benefit of detecting 
and targeting high-risk individuals rather than implementing population-wide diabetes 
prevention strategies is also largely unknown.
28
  These are potential areas of further 
research to assess most effective prevention strategies and approaches.   
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The preliminary findings from the impact studies covered in the systematic review also 
suggest that not everyone at high risk is interested in coming forward for individual 
preventive input, nor will they necessarily stay the course of such input.  Researching 
which factors buck this trend could result in improved prevention in the future.   
 
We know from cohort studies that early detection of established diabetes improves 
outcome, though the evidence base for screening the entire population is weak.
157 158
  In 
those with impaired glucose tolerance or impaired fasting glucose, landmark trials from 
China,
159
 Finland
160
 and USA
161
 reduced incident cases of type 2 diabetes by up to 33%, 
50% and 58% respectively via lifestyle changes (increased exercise, weight loss) and/or 
pharmacotherapy, though changes may be more modest in a non-trial population.  The 
evidence base for interventions that reliably reduce risk (and therefore incidence) of type 2 
diabetes in otherwise healthy adults with normal glycaemic indices is very sparse.  At the 
population level for individuals without diabetes (who may or may not have abnormal 
glycaemic indices) research indicates that the more behavioural goals that can be attained 
over time (controlling weight, diet and physical activity) the lower the incidence of type 2 
diabetes in the long term.
162
  Yet, despite the emerging ability to quantify diabetes risk, 
there is at present a lack of evidence about how to reduce incidence of diabetes in those at 
risk of diabetes (as oppose to those with pre-diabetes).  More research is needed in this 
area.  For example, a large multicentre randomised control trial comparing different 
interventions (e.g. lifestyle changes, metformin, and placebo).   
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Using small area maps to plot risk of chronic disease at a local level is relatively novel.  It 
informs visualisation of important social determinants of health which may generate 
engagement of people with an interest (including local populations) in research and targeted 
initiatives for improvement.  However, the use of this technique beyond the research 
environment may be limited by governance and technical factors and by the specialist skills 
needed for the data extraction and mapping.  The methodology could be refined through 
further research of potential utility, to improve geospatial mapping for public health 
planning.  Further studies of feasibility, impact and cost are needed, as are published 
information governance guidance on how to handle patient level data for geospatial 
mapping.   
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Reflections on the thesis 
 
When I approached Professor Greenhalgh and expressed a desire to improve my academic 
skills in her department, I could not have imagined that so much would have been achieved.   
 
I learned a great deal about systematic review methodology, both quantitative and 
qualitative, and was able to learn how an intractably complex area, which started with a 
search which generated almost 15,000 research papers, could be distilled into one key table 
of readily usable risk scores, ready for application in healthcare.  Systematic reviewing is 
not without its difficulties.  Much is dependent on the decisions of the researchers, and I 
was fortunate to be working with a Professor who demanded a high standard of research 
with appropriate checks and balances.  It was frustrating, if something was changed in the 
data extraction to have to have a second researcher double check the change, but taught me 
about the importance of striving for the highest standards in academic research.   
 
The cross-sectional study taught me a lot about the management of enormous databases, 
how complex they are, the degree of error that is inherent when hundreds of thousands of 
records are being extracted, cleaned and analysed, and the potential such analysis has for 
informing population wide interventions.  Having firsthand experience of working with 
such a large database has given me an understanding of the daily workload of data analysts 
and the time it takes to extract and clean data.  Previously when I worked at the Department 
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of Health I took this for granted; now I can appreciate how much background work is 
required.   
 
Geospatial mapping in an academic context was a new experience for me, and I learned a 
lot about using Excel, GIS and Adobe Illustrator.  The time involved to manipulate data and 
map it at first surprised me and has again given me an appreciation of how asking for a map 
of certain data has vastly more to it that just hitting an imaginary ‘map it’ button on a 
computer.  Handling postcode level information was complex, and at times dealing with the 
governance issues surrounding extraction, handling, and mapping was stressful.  I am 
grateful to colleagues and the NIGB for their advice and assistance in this process.  I erred 
on the side of caution with these issues, and it has taught me a great deal about data 
protection, which I am already applying within my NHS practice.   
 
The media experience was a bonus to the overall research, and taught me much about how 
the press report research.  It has whetted my appetite for more work of that nature in the 
future, although I recognise the risk that a misplaced word or phrase can do.   
 
In summary I enjoyed this research very much, was able to work and learn from highly 
skilled and able colleagues, and am in a position to now apply the findings in the wider 
NHS.   
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Appendix 1: Systematic review study protocol 
 
STUDY PROTOCOL for Noble et al: Systematic review on diabetes risk scores (BMJ 
2011/889725) 
Objectives 
Objectives 1. To summarise characteristics and statistical properties of 
diabetes risk scores.   
2. To evaluate the impact of such scores in improving patient-
relevant outcomes 
Methods: Criteria for considering studies for this review: 
Eligibility criteria for study 
design 
For development and validation of risk scores: prospective 
cohort studies.  For impact studies: any design which illuminates 
(qualitative) or measures (quantitative) the impact of a score on 
a patient-relevant outcome. 
Eligibility criteria for patient 
population 
Adults over 18 without diabetes at baseline.   
Specification of primary 
endpoint (including 
measurement instrument) 
Development of type 2 diabetes by any measurement technique.   
Details of subgroups No subgroups for analysis were predefined in the study protocol.   
Methods: Search methods:  
Identification of studies See Appendix submitted with main paper (briefly, search by 
experienced librarian and researcher of MEDLINE, Pre-
MEDLINE, EMBASE + Cochrane) plus reference search.   
Efforts to identify ongoing 
studies 
Citation track of all included papers in Google Scholar by two 
researchers independently.   
Efforts to identify foreign-
language studies 
All foreign-language papers deemed relevant according to 
inclusion and exclusion criteria from the main search were 
translated by bilingual academics assisted by one of the research 
team.   
Methods: Data collection and analysis: 
List of included studies See Table 1a, 1b and 1c in supplementary material.   
Analysis method Heterogeneity of primary studies precluded formal statistical 
meta-analysis.   
Quantitative data were presented in disaggregated form and 
simple descriptive statistics (e.g. median/range) used to 
highlight patterns in the data across studies.   
Qualitative data were analysed using realist methodology.   
Management and co-ordination of study: 
Management structure of 
research team 
Core research group chaired by DN and included TG, RM, TD 
and CM.   
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Data management and quality 
assurance 
Primary extraction of quantitative data was double checked by a 
second researcher.   
A one third sample of the qualitative data was double checked 
by a second researcher.   
Disagreements were resolved by discussion and at team 
meetings.   
Responsibility for statistical 
analysis 
DN and TD.  All presented statistics were discussed at research 
team meetings.   
Publication policy: 
Criteria for authorship All researchers meeting BMJ criteria for authorship.   
Writing of paper See ‘contributorship’ statement in main paper.   
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Appendix 2: MOOSE checklist 
 
Addressed Criterion Brief description of how the criteria were 
handled in the review 
Reporting of background  
 Problem definition Diabetes risk scores have existed in the 
literature for almost 20 years, yet there is 
confusion amongst GPs and commissioners 
about [a] the usefulness of the scores [b] which 
score to use.  We therefore systematically 
reviewed diabetes risk scores to assess their 
performance and impact.   
 Hypothesis to be tested [a] There exist diabetes risk scores which are 
sufficiently sensitive, specific and 
discriminatory to have a significant potential 
impact on patient outcome and [b] such scores 
have actually had such an impact.   
 Description of study 
outcomes 
Performance as assessed by discrimination, 
calibration, generalisability and external 
validation.   
Impact as assessed by citation tracking and 
realist review.   
 Type of exposure  Not applicable (risk score validation studies are 
not designed to assess exposure).   
 Type of study designs used For development and validation of risk scores: 
prospective cohort studies.  For impact studies: 
any design which illuminates (qualitative) or 
measures (quantitative) the impact of a score on 
a patient-relevant outcome. 
 Study population Adults over 18 free of diabetes at baseline.   
Detailed demography and outcomes extracted 
and reported in main paper and in detailed 
Tables 1a, 1b + 1c.   
Reporting of search strategy should include 
 Qualifications of searchers Helen Elwell MSc Experienced Librarian at 
BMA Library, Douglas Noble BM BCh MPH, 
Catherine Meads previously of NICE 
Systematic Review Team.  Trish Greenhalgh 
MD, Professor. 
 Search strategy, including 
time period included in the 
synthesis and keywords 
Time period: from inception of MEDLINE, 
EMBASE and Cochrane Library to February 
11
th
 2011.   
Search strategy – see submitted Appendix.   
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 Databases and registries 
searched 
MEDLINE, Pre-MEDLINE, EMBASE and 
Cochrane Library.   
 Search software used, name 
and version, including 
special features 
Ovid was used to search MEDLINE, Pre-
Medline and EMBASE.   
ENDNOTE was used to remove duplicates.   
 
 Use of hand searching We searched references of final included papers 
and other key references.   
 List of citations located and 
those excluded, including 
justifications.   
Citations were excluded according to exclusion 
criteria on p8 of the submitted manuscript.  
Citations describing impact were also reviewed.   
 Method of addressing 
articles published in 
languages other than 
English 
We placed no restrictions on language; 
bilingual academic colleagues translated 
relevant sections of included papers in dialogue 
with one of the research team who completed 
data extraction forms.   
 Method of handling 
abstracts and unpublished 
studies 
Some studies were excluded on basis of 
abstract review alone according to exclusion 
criteria.   
Unpublished studies were excluded.   
 Description of any contact 
with authors 
Selected authors were contacted as needed to 
clarify details of study or enquire if further 
publications.   
Reporting of methods should include 
 Description of relevance or 
appropriateness of studies 
assembled for assessing the 
hypothesis to be tested 
Table of included studies 1a, 1b + 1c submitted.   
 
 
 
 Rationale for the selection 
and coding of data 
We extracted data from regression models 
reporting risk factors for developing type 2 
diabetes.  This was agreed by the project team.  
See Tables 1a, 1b + 1c submitted.   
 Assessment of confounding Confounding is discussed on p17 of the 
submitted manuscript.   
 Assessment of study 
quality, including blinding 
of quality assessors; 
stratification or regression 
on possible predictors of 
study results 
Studies which met performance criteria with 
regard to discrimination, calibration, 
generalisability and external validation were 
independently double-checked by two 
researchers and agreed by the project team.  
Meta-analysis was not possible owing to 
statistical heterogeneity as agreed by the project 
team and after consultation with other statistical 
experts.   
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 Assessment of 
heterogeneity 
Gross heterogeneity precluded meta-analysis.   
 Description of statistical 
methods in sufficient detail 
to be replicated 
Descriptive statistics presented in detail in 
Tables 1a, 1b and 1c.   
 Provision of appropriate 
tables and graphics 
See Figure 1+2, Table 1 +2, Tables 1a, 1b and 
1c.   
Reporting of results should include 
 Graph summarizing 
individual study estimates 
and overall estimate 
Individual risk factors for each diabetes risk 
score presented in Tables 1a, 1b + 1c.  Also 
described on p13 of submitted manuscript.   
 Table giving descriptive 
information for each study 
included 
See Table 1+2, Tables 1a, 1b and 1c.   
 Results of sensitivity 
testing 
Not applicable as meta-analysis precluded.   
 Indication of statistical 
uncertainty of findings 
Addressed in results and discussion section of 
submitted manuscript.   
Reporting of discussion should include 
 Quantitative assessment of 
bias 
Discussed on p17 of submitted manuscript.   
 Justification for exclusion All studies were excluded based on the pre-
defined inclusion criteria.   
 Assessment of quality of 
included studies 
Discussed on p18 of submitted manuscript.   
Reporting of conclusions should include 
 Consideration of alternative 
explanations for observed 
results 
A broad discussion of limitations, impact and 
future use of risk scores is included in the 
discussion of submitted manuscript.   
 Generalization of the 
conclusions 
Conclusions are linked to impact and further 
research is suggested in several areas.   
 Guidelines for future 
research 
See p21 of submitted manuscript.   
 Disclosure of funding 
source 
See statement on p28 of submitted manuscript.   
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Appendix 3: Search strategy for systematic review 
 
Database: Ovid MEDLINE(R) <1948 to February week 1 2011> Search Strategy: 
-------------------------------------------------------------------------------- 
1     diabetes mellitus, type 2/ or prediabetic state/ (64110) 
2     diabetes.tw. (233161) 
3     ("type 2" or type two or type ii or type II).tw. (131044) 
4     2 and 3 (46990) 
5     1 or 4 (77482) 
6     prediabetic state.tw. (208) 
7     pre-diabetic.tw. (396) 
8     6 or 7 (602) 
9     5 or 8 (77756) 
10     odds ratio/ or exp risk/ or regression analysis/ or "sensitivity and specificity"/ or roc 
curve/ (935102) 
11     (risk adj3 (score$ or predict$ or factor$ or model$ or assess$ or calculat$ or analys$ 
or screen$)).tw. (298546) 
12     10 or 11 (1044213) 
13     9 and 12 (19631) 
14     limit 13 to humans (19334) 
15     limit 14 to (classical article or clinical trial, all or clinical trial, phase i or clinical trial, 
phase ii or clinical trial, phase iii or clinical trial, phase iv or clinical trial or comparative 
study or controlled clinical trial or "corrected and republished article" or evaluation studies 
or introductory journal article or journal article or meta analysis or multicenter study or 
randomized controlled trial or "review" or technical report or validation studies) (18375) 
16     *diabetes mellitus, type 2/ or *prediabetic state/ (49993) 
17     15 and 16 (12176) 
18     11 and 17 (6169) 
*************************** 
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Database: EMBASE <1980 to 2011 Week 05> Search Strategy: 
-------------------------------------------------------------------------------- 
1     non insulin dependent diabetes mellitus/ (92300) 
2     diabetes.tw. (300352) 
3     ("type 2" or type two or type ii or type II).tw. (161037) 
4     2 and 3 (66250) 
5     1 or 4 (108295) 
6     non-insulin dependent.tw. (11795) 
7     (prediabetic state or pre-diabetic).tw. (793) 
8     6 or 7 (12565) 
9     5 or 8 (111058) 
10     RISK ASSESSMENT/ or RISK FACTOR/ or RISK/ (732204) 
11     LOGISTIC REGRESSION ANALYSIS/ (33553) 
12     "sensitivity and specificity"/ (133377) 
13     receiver operating characteristic/ (14334) 
14     (risk adj3 (score$ or predict$ or factor$ or model$ or assess$ or calculat$ or analys$ 
or screen$)).tw. (381302) 
15     10 or 11 or 12 or 13 or 14 (1013026) 
16     9 and 15 (25922) 
17     limit 16 to human (22923) 
18     14 and 17 (12551) 
19     *non insulin dependent diabetes mellitus/ (58830) 
20     18 and 19 (6947) 
*********************** 
 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations  
<February 09, 2011> Search Strategy: 
-------------------------------------------------------------------------------- 
1     diabetes.tw. (10421) 
2     ("type 2" or type two or type ii or type II).tw. (5982) 
3     prediabetic state.tw. (7) 
4     pre-diabetic.tw. (22) 
5     (risk adj3 (score$ or predict$ or factor$ or model$ or assess$ or calculat$ or analys$ or 
screen$)).tw. (14580) 
6     1 and 2 (3254) 
7     3 or 4 or 6 (3271) 
8     5 and 7 (524) 
*************************** 
 
COCHRANE LIBRARY 
Search History: 
#1  MeSH descriptor Diabetes Mellitus, Type 2, this term only  6547 
#2  MeSH descriptor  Risk explode all trees    23562 
#3 (#1 AND #2)         716 
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Appendix 4: BMJ paper of systematic review 
 
Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 
diabetes: systematic review. BMJ 2011;343:d7163. 
 
Can be accessed online at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225074/ and 
http://www.bmj.com/content/343/bmj.d7163  
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Appendix 5: Submitted BJGP paper of cross-sectional study 
 
This paper is now in press, and will contain some additional material with updates and 
minor corrections: 
 
Mathur R, Noble D, Smith D, Greenhalgh T, Robson J. Quantifying risk of type 2 diabetes 
in East London using the QDScore.  British Journal of General Practice.  In press.   
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Appendix 6: BMJ Open paper of geospatial mapping study 
 
Noble D, Smith D, Mathur R, Robson J, Greenhalgh T. Feasibility study of geospatial 
mapping of chronic disease risk to inform public health commissioning. BMJ Open 
2012;2(1):e000711. 
 
Can be accessed online at: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282296/?tool=pubmed and 
http://bmjopen.bmj.com/content/2/1/e000711.full  
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Appendix 7: Submitted BMC Public Health paper of mapping and information 
governance 
 
This paper was peer reviewed by BMC Public Health.  It is currently being revised, and the 
plan is for it to be submitted to a different journal.   
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